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Introduction  Fibrinolytic shutdown plays a pivotalrole in the 
pathogenesis of multiple organ dysfunction syndrome (MODS) in 
disseminated intravascular coagulation (DIC).We tested the hypothesis 
that the levels of thrombin activatable fi  brinolysis inhibitor (TAFI) are 
not suffi   cient to overcome fi  brinolytic shutdown, thus contributing to 
MODS and the poor prognosis in sepsis-induced DIC.
Methods Fifty patients with sepsis, severe sepsis, or septic shock were 
enrolled in the study. The DIC was diagnosed based on the Japanese 
Association for Acute Medicine (JAAM) DIC criteria. The overt DIC scores 
based on the International Society on Thrombosis and Haemostasis 
(ISTH) were also calculated. On the day of sepsis diagnosis (day 1), and 
days 3 and 5, we measured TAFI, soluble fi  brin, and global coagulation 
and fi  brinolysis markers.
Results The JAAM DIC scores on day 1 and maximum JAAM DIC scores 
were independent predictors of patient death and MODS, respectively. 
The JAAM DIC patients, especially those who simultaneously met the 
ISTH overt DIC criteria, showed lower TAFI antigen levels and activity, 
and higher levels of soluble fi  brin in comparison with non-DIC patients. 
There were diff  erences in the levels of soluble fi  brin and TAFI activity 
between the patients with and without MODS. The fi  ndings of stepwise 
logistic regression and multiple regression analyses suggested that low 
TAFI activity is an independent predictor of patient death and MODS. A 
multiple regression analysis also indicated that soluble fi  brin negatively 
correlated with the TAFI activity in DIC patients.
Conclusion Thrombin activation results in the consumption of TAFI. 
Low TAFI activity is involved in the pathogenesis of DIC-induced MODS 
and poor prognosis.
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Introduction Anti-endotoxin immunity (AEI) has many biological eff  ects 
but the problem of conjugation and elimination of lipopolysaccharides 
(LPS) in peritonitis patients is not discussed. We investigated the role 
of IgA, IgM and IgG in peritonitis and their association with humoral 
immunity (HI).
Methods We investigated 33 patients (male:female = 25:8) with ab-
domi  nal sepsis (total peritonitis in appendicitis, perforated duodenal 
ulcer, pancreonecrosis). Anti-endotoxin (AE) antibodies (anti-LPS-IgA, 
anti-LPS-IgM, anti-LPS-IgG) were determined by original modifi  cation 
of hard-phase immunoenzyme analysis. Escherichia coli K30 LPS 
was used as antigen for AE antibody detection. The level of general 
immunoglobulin was determined by the microturbidimetric method 
with human monospecifi  c sera to IgG, IgA and IgM. All data were 
compared with healthy donors (99 patients).
Results A high level of AEI and HI was determined in 24% of patients 
who recovered rapidly without complication after surgery, discharged 
in 9 to 10 days. This was confi  rmed by clinical data (normalization of 
body temperature, peristalsis, spontaneous stool) by 4 to 5 days. A low 
level of AEI and HI was found in 42% of patients who recovered slowly; in 
a favorable course of peritonitis, the increase of parameters was marked 
by 8 to 10 days; in several with suppuration of wounds, discharge was 
in 14 to 16 days. A few patients with a low level of immunity against the 
background of abdominal sepsis required therapy with sandoglobulin 
H that was accompanied with a sharp positive change of a postoperative 
course of peritonitis and an increase of immunity indices. See Table 1. 
An evident decrease of AE antibodies may be a background for 
translocation of endotoxin from the intestine to the portal and systemic 
circulation. Disorder of AE mechanisms of endotoxin conjugation may 
activate other mechanisms of neutralization (endotoxin-conjugating 
protein) that stimulate CD14-receptor structures and mechanisms of 
active production of proinfl  ammatory cytokines and starting systemic 
infl  ammatory response syndrome.
Conclusion Abdominal sepsis patients are determined dysfunction of 
AEI (decrease of AE IgM and IgG). Successful treatment of peritonitis 
is accompanied with normalization of the IgM and IgG concentration 
and an increase of IgA above standard. Dynamics of AE antibodies may 
be a marker of the clinical course and forecast of abdominal sepsis. 
Comparative analysis of HI and AEI demonstrates parallelism of the 
dynamic concentration of immunoglobulins during treatment.
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Table 1 (abstract P2)
 AEI  HI
  IgA IgG IgM IgA IgG IgM
  Before After Before After Before After Before After Before After Before After
  surgery surgery surgery surgery surgery surgery surgery surgery surgery surgery surgery surgery
Peritonitis   0.28 ± 0.01,  0.45 ± 0.02  0.12 ± 0.01,  0.13 ± 0.02  0.21 ± 0.03,  0.29 ± 0.04  2.26 ± 0.16,  2.77 ± 0.18  10.1 ± 0.47,  10.98 ± 0.5  1.39 ± 0.11,  1.56 ± 0.12
patients  P <0.05  P <0/01  P <0/05   P >0.5  P >0.5   P <0.05 
Donors   0.35 ± 0.05    0.16 ± 0.01    0.33 ± 0.05    2.21 ± 0.08    10.54 ± 0.242    1.66 ± 0.06 
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Introduction  CD14 is present in macrophage, monocyte, and 
granulocyte cells and their cell membranes, and its soluble fraction 
is present in blood and is thought to be produced in association with 
infections. It is called the soluble CD14 subtype, and its generic name 
is presepsin. Presepsin is a novel marker for the diagnosis of sepsis, and 
the results of previous study in which an ELISA kit was used showed 
a specifi  c increase in sepsis in the early stage that also correlated 
well with severity. In the present study we developed a new rapid 
measurement method for whole blood that use a chemiluminescence 
enzyme immunoassay. We assessed the usefulness of presepsin values 
in sepsis.
Methods The period of the study was the 10 months from August 2009 
to June 2010. The subjects were 41 in-patients, age 62 ± 19 years old, 
who had been brought to the Critical Care and Emergency Center of 
Iwate Medical University and who fulfi  lled at least two of the diagnostic 
criteria for systemic infl   ammatory response syndrome (SIRS) on 
arrival. Blood specimens were collected a total of six times; that is, on 
admission, and 12 and 24 hours and 3, 5, and 7 days later. Presepsin 
values were measured by immunoassay analyzer (PATHFAST; Mitsubishi 
Chemical Medience Corporation, Japan). The sepsis marker PCT, IL-6, 
and CRP were also measured for comparison. In addition, 128 healthy 
subjects were assessed as controls.
Results The mean presepsin level in the 128 healthy subjects in the 
control group was 190 pg/ml. The corresponding presepsin levels were 
normal (non-infection), 294.2 ± 121.4 pg/ml; local infection, 721.0 ± 
611.3 pg/ml; SIRS, 333.5 ± 130.6 pg/ml; sepsis, 817.9 ± 572.7 pg/ml; and 
severe sepsis, 1,992.9 ± 1,509.2 pg/ml; the patients with local infection 
or sepsis had signifi  cantly higher presepsin levels than the patients 
who did not have infection as a complication. In addition, the presepsin 
levels in SIRS that was not complicated by infection were signifi  cantly 
lower than in sepsis. When we divided the patients into an infection 
group and a no infection group and plotted the ROC curves of each 
of the markers to compare presepsin with other markers, the results 
showed that presepsin was the best.
Conclusion We were able to obtain results similar to those obtained 
with the conventional ELISA method, and it was possible to diagnose 
sepsis more rapidly and conveniently using the immunoassay analyzer.
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Introduction Endotoxin activity assay (EAA) levels were compared with 
endotoxin levels determined by the turbidimetric kinetic method.
Methods  A specifi  c method for the measurement of endotoxin, in 
the blood of patients under various conditions, and the infl  uence 
of steroids on EAA levels and contamination of tubes used for the 
measurements were investigated.
Results  EAA levels increased in patients with injuries and acute 
pancreatitis. EAA levels did not increase in patients infected with Gram-
positive bacteria. Endotoxin levels determined by the turbidimetric 
kinetic method did not increase in patients with injuries and acute 
pancreatitis and Gram-positive bacteria. When patients with long-
term steroid use developed shock due to infection with Gram-negative 
bacteria, EAA levels did not increase but endotoxin levels determined 
by the turbidimetric kinetic method increased. EAA levels, but not 
endotoxin levels determined by the turbidimetric kinetic method, 
were suppressed by giving steroids in vitro. Endotoxin was detected 
in the tubes used for the measurements. This was suppressed by the 
addition of polymyxin B and anti-factor C antibody. EAA levels tended 
to increase immediately after direct hemoperfusion using a polymyxin-
B-immobilized fi  ber column (PMX-DHP).
Conclusion Our fi  ndings suggest that the EAA had limitations as a 
method to measure endotoxin.
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Introduction Tight glycemic control is a major concern in critical care. 
The objective of this study in the ICU was to evaluate the eff  ectiveness 
and safety of the Yale insulin infusion protocol in sepsis patients.
Methods  A retrospective, before–after cohort study. Selected end-
points were mean blood glucose levels, time to reach the target range 
of 100 to 150 mg/dl, percentage of blood glucose in the target range, 
and hypoglycemia incidence.
Results Were studied 78 patients: 42 in the control group (CG) and 36 
in the protocol group (PG). Bedside blood glucose was measured 3,755 
times for a mean value of 134.1 ± 15.4 mg/dl in the PG versus 1,730 
times for a mean value of 172.7 ± 33.6 mg/dl in the CG. Blood glucose 
values were in the target range 63% and 37% of the times, respectively, 
for the PG and the CG (P <0.001). The median time to reach the glucose 
target range was 8 hours (range 5 to 17 hours) for the PG and 53 hours 
(range 23 to 218 hours) for the CG (P <0.001). The incidence of severe 
hypoglycemia reached a statistically signifi  cant diff  erence: one patient 
in the PG versus four patients in the CG (P <0.01). All patients reached 
the target in 72 hours of insulin infusion in the PG while only 29 patients 
in the CG reached this target.
Conclusion The Yale insulin infusion protocol was eff  ective and safe in 
sepsis patients admitted to the ICU.
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Introduction  Vasopressin is frequently used to maintain blood 
pressure in refractory septic shock. We hypothesized that early infusion 
of vasopressin compared with norepinephrine would decrease the 
mortality rate and severity of septic status.
Methods In this randomized, double-blind study, we assigned patients 
who need vasopressors and randomized to receive norepinephrine 
(0.05 to 2.0  μg/kg/minute) or vasopressin (0.01 to 0.03  U/minute) 
with norepinephrine. Both groups had the vasoactive drug infusions 
titrated and tapered to maintain a mean blood pressure between 65 
and 75 mmHg.
Results A total of 387 patients underwent randomization with 191 
patients receiving vasopressin and 196 receiving norepinephrine. 
There was no signifi   cant heterogeneity between these two study 
groups. There was a signifi  cant diff  erence between the vasopressin and 
norepinephrine groups in the mortality rate of 14 days (29.3% vs. 36.7%, 
respectively, P = 0.05) and 28 days (34% and 42.3%, respectively, P = 
0.03); however, in 7-day mortality there were no signifi  cant diff  erences 
in the overall rates (21.2% vs. 23.9%, respectively; P = 1.1). Also note 
a reduction in the incidence of single organ dysfunction (37.7% vs. 
49.2%, respectively, P = 0.02) and multiple organ dysfunction using 
vasopressin and norepinephrine (17.8% vs. 26%, P = 0.05; P = 0.03). The 
length of stay in the ICU was 14 and 17 days (P = 0.29) and the time 
of hospitalization was 23 and 28 days (P = 0.11), respectively, in the 
vasopressin and norepinephrine groups.
Conclusion Early application of vasopressin reduced mortality rates 
in 14 and 28 days as compared with norepinephrine alone, and also a 
diff  erence in incidence of organ dysfunction. This observed diff  erence 
can be attributed to early restoration of tissue perfusion and vascular 
smooth muscle responsiveness that directly infl  uenced patient survival.
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Introduction Many symptoms of septic shock are due to the presence 
of endotoxin in the bloodstream. The biological activity of endotoxins 
is associated with lipopolysaccharide (LPS). LPS induces systemic 
infl   ammatory response and a high level of endotoxin in blood is 
associated with worse clinical outcome. Reduction of the level of 
circulating endotoxins with hemoperfusion through the fi  lter  with 
high affi   nity for LPS could potentially interrupt the biological cascade 
of sepsis. The aim of the study was to evaluate the effi   ciency  of 
extracorporeal endotoxin elimination in patients with Gram-negative 
septic shock.
Methods The study was conducted at the Department of Anesthes-
iology and Intensive Therapy, Wroclaw Medical University, Poland. 
Patients with septic shock, documented or suspected Gram-negative 
infection, and with high endotoxin activity (EA >0.6 units) were 
eligible for the study. The endotoxin activity in blood was measured 
with chemiluminescent activity assay. Based on the enrolment criteria 
and EA level, patients were assigned to the conventional treatment 
group (Group 1) or the conventional plus hemoperfusion therapy 
with LPS adsorber (Alteco Medical AB, Lund, Sweden) group (Group 2). 
Hemoperfusion was performed for 2 hours with blood fl  ow maintained 
at 150 ml/minute.
Results Seventeen patients with low EA (0.42 ± 0.14, Group 1) and 12 
patients with high EA (0.76 ± 0.13, Group 2) (P <0.05) were included. 
There were no signifi  cant diff  erences between Group 1 and 2 regarding 
age (63 ± 2 and 61 ± 21), APACHE II score (22.7 ± 8.6 and 24.5 ± 7.2), 
SOFA score (9.8 ± 3.0 and 11.3 ± 4.1), mean arterial pressure (MAP, 66.2 ± 
8.1 mmHg and 71.5 ± 7.3 mmHg), and PaO2/FiO2 (255 ± 59 and 216 ± 
105) at entry to the study. In the hemoperfusion group, nine patients 
had Gram-negative and three had Gram-positive infection; seven 
patients survived to the 28-day follow-up. High endotoxin activity at 
baseline decreased signifi  cantly 24 hours after hemoperfusion to 0.5 ± 
0.1 (P <0.01) in those who survived, but remained high (0.7 ± 0.1) in 
nonsurvivors. At 24 hours after hemoperfusion, MAP signifi  cantly 
increased (78.8 ± 20.8 to 89.2 ± 19.8 mm Hg, P <0.05) and vasopressor 
requirements decreased in survivors but not in those who died (MAP, 
64.2 ± 9.6 to 71.8 ± 15.3 mm Hg, P = nonsignifi  cant).
Conclusion Hemoperfusion with LPS adsorber added to standard 
treatment improved the hemodynamic status of patients with septic 
shock. The chemiluminescence assay for measurement of LPS activity 
was a valuable diagnostic tool for rapid detection of endotoxemia.
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Introduction Urinary proteomics have recently identifi  ed hepcidin, a 
key regulator of iron homeostasis, as a potential marker of tubular stress 
[1]. It appears to be released in response to situations that predispose 
to acute kidney injury (AKI), and greater concentrations of hepcidin 
in the blood and in the urine have been associated with reduced risk 
of AKI [2]. Catalytic iron is a biologically plausible mechanism for the 
development of AKI as a consequence of tubular oxidative stress [3]. 
The relationship between serum creatinine, urinary hepcidin and CRP 
may help defi  ne whether urinary hepcidin is more likely to refl  ect 
systemic infl   ammation or renal events. The relationship in septic 
patients has not yet been described. Patients with SIRS, oliguria and 
a 25 μmol/l increase from baseline creatinine are known to be at an 
increased risk of AKI [4]. We sought to determine if hepcidin correlated 
more strongly with CRP or creatinine in these patients with a diagnosis 
of sepsis and those without.
Methods Patients meeting the inclusion criteria within 48 hours of 
admission had their CRP, urinary hepcidin, and serum and urinary 
creatinine measured. The strength of the relationship between serum 
creatinine or CRP and urinary hepcidin corrected for urinary creatinine 
was determined using Spearman’s rank correlation coeffi   cient.
Results We enrolled 103 patients between 31 August 2010 and 17 
November 2010; 22 of whom had an APACHE III diagnosis of sepsis. 
Serum creatinine only correlated weakly with direct and inverse 
urinary hepcidin measurements in septic and nonseptic patients alike. 
However, there was a moderately strong correlation between CRP and 
urinary hepcidin in septic patients, a relationship not demonstrated in 
the nonseptic group (Table 1).
Table 1 (abstract P8). Relationships between hepcidin, creatinine and CRP
 Correlation
 Nonseptic  (n = 81)  Septic (n = 22)
Variable  Serum Cr  CRP  Serum Cr  CRP
Urinary hepcidin  –0.272   0.204  –0.225  0.506
 ( P = 0.013)  (P = 0.064)  (P = 0.314)  (P = 0.016)
1 / urinary hepcidin  0.287   –0.19  0.225  –0.506
 ( P = 0.009)  (P = 0.087)  (P = 0.314)  (P = 0.016)
Urinary hepcidin   –0.146  0.241  –0.276  0.418
corrected for   (P = 0.191)  (P = 0.029)  (P = 0.227)  (P = 0.06)
urinary creatinine 
1 / urinary hepcidin   0.158  –0.228  0.276  –0.418
corrected for   (P = 0.159)  (P = 0.041)  (P = 0.227)  (P = 0.06)
urinary creatinine
Conclusion Hepcidin is only weakly inversely correlated with serum 
creatinine. A stronger relationship exists between hepcidin and CRP in 
septic patients, suggesting that hepcidin may primarily be a marker of 
infection that is fi  ltered in the urine when the glomerular fi  ltration rate 
(GFR) is preserved and fi  ltered in lower amounts when the GFR is lost. 
That this relationship is not replicated in nonseptic patients with clinical 
evidence of SIRS suggests that the underlying pathophysiological 
processes are diff  erent. Further investigation of the natural history of 
AKI and biomarker release is warranted.
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Introduction Neutrophil gelatinase-associated lipocalin (NGAL) predicts 
the development of acute kidney injury (AKI) amongst critically ill 
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S3patients [1]. Serum and urinary NGAL have been shown to be elevated 
in patients with SIRS, sepsis and septic shock [2], and the predictive 
ability of NGAL in these patients is not so certain [3]. It is unclear, 
however, whether this predictive relationship is due to the fact that 
NGAL is produced by neutrophils and is, therefore, a biomarker of 
infl  ammation and infection, or whether NGAL in blood and/or urine 
mostly refl  ects tubular release. It is also unclear if the type of AKI that 
develops in SIRS is diff  erent from that developing in septic patients.
Methods To test these hypotheses, we studied ICU patients with SIRS 
and oliguria or a 25 μmol/l increase in serum creatinine. We sought 
to determine whether blood and urine NGAL correlated more closely 
with CRP or creatinine at the time of enrolment. The strength of the 
relationship between serum creatinine or CRP and urine and serum 
NGAL, as well as urinary NGAL corrected for urinary creatinine, was 
determined using Spearman’s rank correlation coeffi   cient.
Results We recruited 105 patients between 31 August 2010 and 17 
November 2010; 22 of these had an APACHE III diagnosis of sepsis. 
In nonseptic patients NGAL in blood or urine correlated only weakly 
with CRP, but a stronger and statistically signifi  cant relationship was 
observed between serum and/or urine NGAL and serum creatinine. A 
similar strength of relationship was observed between creatinine and 
NGAL and CRP and NGAL in septic patients, although it failed to reach 
signifi  cance. See Table 1.
Table 1 (abstract P9). Relationships between NGAL, creatinine and CRP in 
patients with and without sepsis
 Correlation
 Sepsis  (n = 22)  No sepsis (n = 83)
Variable  Serum Cr  CRP  Serum Cr  CRP
Urinary NGAL  0.345   0.302  0.391  0.057
 ( P = 0.116)  (P = 0.173)  (P <0.001)  (P = 0.61)
Urinary NGAL   0.311  0.235  0.514  0.070
corrected for   (P = 0.171)  (P = 0.305)  (P <0.001)  (P = 0.532)
urinary creatinine
Serum NGAL  0.244   0.411  0.661  –0.034
 ( P = 0.274)  (P = 0.057)  (P <0.001)  (P = 0.763) 
Conclusion In patients without a diagnosis of sepsis, NGAL is only 
weakly correlated with CRP and a stronger relationship is observed 
between NGAL and serum creatinine. This suggests that NGAL is 
more likely a biomarker of tubular injury or stress than systemic 
infl   ammation in these patients. Similar relationships of moderate 
strength are observed between NGAL in blood/urine and both 
serum creatinine and CRP in patients with a diagnosis of sepsis. This 
suggests that diff  erent pathophysiological processes may exist in the 
genesis of septic AKI when compared with infl  ammatory AKI. Further 
investigation regarding the natural history of AKI and the clinical and 
biochemical association of renal biomarkers is warranted.
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Introduction  The utility of urinary biochemistry has recently been 
challenged [1], while there is emerging evidence that renal biomarkers 
may accurately quantify the risk of development of acute kidney injury 
(AKI) [2]. Neutrophil gelatinase-associated lipocalin (NGAL) is a marker 
of renal tubular damage [3]. Fractional excretion of sodium (FENa) 
is a marker of renal tubular function, and is a signifi  cantly cheaper 
investigation [4]. Insults damaging the tubules and resulting in AKI 
should both stimulate NGAL production and prevent resorption of 
sodium. Given the diff   erent pathological mechanisms underlying 
septic and nonseptic AKI, it is plausible that the relationship between 
these variables could be diff  erent in these two groups of patients [5].
Methods To test this hypothesis, we studied ICU patients developing 
SIRS and oliguria or a 25 μmol/l increase in serum creatinine within 
48 hours of ICU admission. We sought to determine if a relationship 
existed between FENa and NGAL in patients, with and without sepsis, 
developing AKI. We measured the serum and urinary NGAL, creatinine 
and sodium of patients with SIRS and either oliguria or an increase in 
creatinine within 48 hours of admission to a tertiary referral ICU. Point-
of-care creatinine measurements were used to identify the maximum 
RIFLE category of AKI developed within the fi  rst 5 days of admission. 
The strength of the relationship between variables was determined 
using Spearman’s rank correlation coeffi   cient.
Results  We enrolled 93 patients between 31 August 2010 and 17 
November 2010; 17 had an APACHE III diagnosis of sepsis. Serum NGAL 
and urinary NGAL when corrected for urinary creatinine were found 
to correlate moderately well with FENa in patients without sepsis, a 
relationship that weakens with the progression of AKI in this group. No 
other correlation showed a signifi  cant relationship (Table 1).
Conclusion The lack of a strong correlation FENa and NGAL in patients 
developing RIFLE I and F AKI suggests that changes in NGAL and 
changes in sodium resorption occur as a consequence of diff  erent 
stimuli in the pathogenesis of the syndrome. The absence of any 
observed relationship between NGAL and FENa in septic patients 
suggests a pathological process diff   erent from that underlying 
nonseptic AKI. The small sample size may be a confounding factor.
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  RIFLE  R–F  5  –0.300  0.624 0.500 0.391 0.112 0.858  –0.400  0.505
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Introduction Multiple biomarkers have been proposed for identifying 
patients at risk of developing the syndrome of acute kidney injury 
(AKI) [1]. These biomarkers include urine and serum NGAL, and urinary 
hepcidin. The pathophysiology of AKI in sepsis appears to be primarily 
mediated by immunological, toxic and infl   ammatory factors as 
opposed to renal ischaemia [2]. Diff  erent aetiologies of AKI are likely to 
lead to diff  erential release of serum and urinary biomarkers. We sought 
to determine if the predictive ability of several renal biomarkers for 
predicting AKI varied in the presence of sepsis in the context of routine 
ICU practice.
Methods We measured serum and urinary NGAL and urinary hepcidin 
in patients admitted to the ICU of a tertiary referral hospital with SIRS 
and either oliguria or a 25 μmol/l serum creatinine increase within 
48 hours of admission. We used point-of-care creatinine measurements 
to identify the maximum RIFLE category of AKI within the fi  rst 5 days of 
enrolment. We corrected both urinary biomarkers for urinary creatinine. 
We calculated the reciprocal of hepcidin measurement and noted if 
serum NGAL was greater than the upper limit of normal (149 ng/ml). 
We derived the area under the curve (AUC) for the receiver operating 
characteristic curve (ROC) for all biomarkers.
Results Between 31 August 2010 and 17 November 2010, we enrolled 
92 patients; 17 of these patients had APACHE II diagnoses of sepsis. In 
patients with a diagnosis of sepsis, the predictive ability of all of the 
biomarkers measured was worse than in those without (Table 1).
Conclusion  Although the sample size is limited, there is a marked 
diff  erence in the predictive ability of the measured biomarkers to predict 
AKI between septic and nonseptic patients. All patients admitted met 
the criteria for a diagnosis of SIRS, suggesting that infl  ammation and 
sepsis contribute to the development of AKI via diff  erent pathways. The 
ability of these biomarkers to predict AKI in patients with a diagnosis 
of sepsis in our cohort is limited. Further investigation is needed into 
whether the combination of specifi  c biomarker patterns and clinical 
features can better identify patients at risk, particularly in the setting 
of sepsis. In addition, further work examining the relationship between 
the various biomarkers and the aetiology and natural history of AKI is 
required.
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Introduction While cancer patients are known to be at higher risk for 
infection and subsequent complications, there is a scarcity of data 
regarding incidence and outcome of septic cancer patients admitted 
to ICUs. Hence, we aimed to assess the incidence of cancer patients 
admitted with sepsis to an onco-medical ICU and study their ICU 
course and outcome.
Methods Data were collected prospectively from all cancer patients 
admitted to a specialized onco-medical ICU of a tertiary care hospital, 
over a period of 6 months. Sepsis was defi  ned as per the international 
guidelines. Cancer patients were divided into two groups on the basis 
of presence of sepsis on ICU admission and compared with regard to 
their need for organ support, length of ICU stay and mortality. Severity 
of illness was assessed by APACHE II score and organ failure by SOFA 
score. Qualitative data were analyzed using the chi-squared test or 
Fisher exact test as appropriate and quantitative data were analyzed 
using Student’s t test. P <0.05 was considered signifi  cant.
Results Out of 104 cancer patients admitted during the study period, 43 
(41.3%) patients were admitted with sepsis. Even though there was no 
diff  erence in age (P = 0.13), sex (P = 0.382) and presence of metastasis 
(P = 0.314) among the septic and nonseptic groups of patients, septic 
patients had comparatively higher admission APACHE II (21.4 ± 7 vs. 
18.21 ± 6.9; P = 0.023) and SOFA (6.4 ± 3.8 vs. 4.56 ± 3; P = 0.007) scores, 
required invasive mechanical ventilation (65.1% vs. 19.7%; P = 0.000) 
and vasopressor support (74.4% vs. 19.7%; P = 0.000) more often, had 
a longer ICU stay (10.77 ± 8.4 vs. 7.44 ± 5.5; P = 0.017) and had a higher 
ICU mortality (62.8% vs. 18%; P = 0.000). The odds ratio and relative risk 
Table 1 (abstract P11). AUC ROC for the prediction of AKI
  ROC AUC
  RIFLE R, I or F  RIFLE I or F
  Septic Nonseptic Septic Nonseptic
Test  result  variable  Area SE Area SE Area SE Area SE
Urinary  NGAL  0.367 0.136 0.561 0.068 0.367 0.136 0.633 0.090
Urinary  NGAL  corrected  for  urinary  creatinine  0.417 0.136 0.578 0.066 0.417 0.136 0.670 0.082
Serum  NGAL  0.375 0.162 0.639 0.065 0.375 0.162 0.685 0.087
Serum  NGAL  positivity  0.492 0.158 0.611 0.066 0.492 0.158 0.674 0.082
Urine:serum  NGAL  ratio  0.483 0.140 0.498 0.068 0.483 0.140 0.543 0.081
1  /  urinary  hepcidin  0.508 0.153 0.624 0.066 0.508 0.153 0.611 0.080
1 / urinary hepcidin corrected for urinary creatinine  0.483  0.156  0.598  0.067  0.483  0.156  0.578  0.083
SE, standard error.
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and 3.482 (95% CI = 1.945 to 6.234).
Conclusion A signifi  cant proportion of cancer patients are admitted 
with evidence of sepsis. These patients were generally sicker, required 
more intensive organ support, and had a longer ICU stay and a higher 
ICU mortality than those cancer patients admitted to ICU with other 
acute problems.
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Introduction Certain colloids like albumin and plasma protein fraction 
(PPF) have been derived from human plasma and they are used as plasma 
expanders to treat patients with shock. PPF, which more closely resembles 
plasma in its constituents, contains albumin plus α and β globulins. We 
conducted this study to assess the eff  ect of PPF on need for vasopressors, 
organ support and ICU mortality in patients with septic shock.
Methods A retrospective study was conducted and data were collected 
from the records of patients admitted to a 16-bed neuro and medical 
ICU over a 1.5-year period. All adult patients admitted with septic 
shock and requiring vasopressor support (for more than 6 hours) in 
spite of aggressive fl  uid resuscitation were enrolled. Patients who were 
transferred from some other ICU or ward and those who developed 
shock during their ICU course were excluded from the analysis. Patients 
were divided into two groups: patients in whom PPF was used along 
with resuscitative fl  uids comprised the study group, whereas others 
formed the control group. Patients in these groups were compared 
according to need for organ support, ICU mortality and time taken 
to stop vasopressor agents. PPF (Plasmanate®) was administered 
in a protocolized way at the dosage of 10 to 20 ml/hour for the fi  rst 
48 hours. Development of any complication like allergy or hypotension 
associated with PPF was also noted.
Results There was no signifi  cant diff  erence in the baseline characteristics of 
patients in both groups in terms of age (P = 0.154), sex (P = 0.479), severity 
of illness (APACHE II score, P = 0.356), and presence of organ failure (SOFA 
score, P = 0.105). Among the outcome parameters there was no signifi  cant 
diff  erence in terms of need for renal support (P = 0.814), mechanical 
ventilation (P = 0.776), ICU stay (P = 0.122), hospital stay (P = 0.054) and 
ICU mortality (P = 0.091). However, there was a signifi  cant diff  erence in 
time taken to stop the vasopressors (P = 0.030) (Table 1). There were no 
incidences of any complications or side eff  ects in any group.
Conclusion PPF may be used safely and eff  ectively for initial resuscitation 
of patients with septic shock requiring vasopressor support. It may 
lead to early termination of vasopressor support; however, it did not 
translate to lesser need for organ support or reduced ICU mortality in 
our patient cohort. To demonstrate such benefi  ts, larger multicenter 
trials are warranted.
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Introduction Disease-severity scoring systems have been developed 
for stratifi   cation of ICU patients. These systems have been tested 
and validated in various general medical and surgical ICU patients. 
However, the validity and effi   cacy of these systems, especially the 
newer generation, has not been assessed in patients with sepsis, which 
is the commonest indication for admission to a medical ICU. Hence, we 
conducted this study to assess the performance of various ICU scoring 
systems – Acute Physiology and Chronic Health Evaluation (APACHE) II, 
III, IV; Simplifi  ed Acute Physiology Score (SAPS) II, III; Mortality Prediction 
Model (MPM) II0, III0; and Sequential Organ Failure Assessment (SOFA) 
scores – in septic patients admitted to a medical ICU.
Methods A prospective, observational study was conducted in a tertiary 
care medical ICU and consecutive patients fulfi  lling the diagnostic 
criteria for sepsis during the fi  rst 24 hours of ICU admission were 
included over a 2-year period. Data related to patient demographics 
and that required to compute various scores were recorded. Predicted 
mortality was calculated using original regression formulas. The 
standardized mortality ratio (SMR) was computed for mortality 
prediction. Calibration was assessed by calculating the Lemeshow–
Hosmer goodness-of-fi   t C-statistic. Discrimination was assessed 
by calculating the area under the receiver operating characteristic 
(AUROC) curves. ICU mortality was the primary outcome measure.
Table 1 (abstract P13). Comparison between patient characteristics and ICU 
course among patients in control and PPF groups
Parameter  Control group  PPF group 
of interest  (n = 87)  (n = 99)  P value
Age (years)  64.11 ± 15.4  67.28 ± 14.8  0.154
Sex, male  50 (57.5%)  63 (63.6%)  0.479
APACHE II score  20.69 ± 6.2  21.64 ± 7.6  0.356
PDR  39.51 ± 19.2  42.47 ± 22.5  0.341
SOFA score  9.53 ± 3.5  10.38 ± 3.7  0.105
RBC transfusions  32 (36.8%)  33 (33.3%)  0.735
Renal support  31 (35.6%)  38 (38.4%)  0.814
Mechanical ventilation  50 (57.5%)  60 (60.1%)  0.776
Time taken to stop   70.69 ± 55.2  51.29 ± 64.5  0.030*
vasopressors (hours)
ICU stay (days)  10.38 ± 11.4  13.42 ± 14.8  0.122
Hospital stay (days)  12.91 ± 11.8  16.83 ± 15.3  0.054
ICU mortality  34 (39.1%)  52 (52.5%)  0.091
*P <0.05. Bold text indicates statistically signifi  cant.
Table 1 (abstract P14). Comparison of the actual and predicted mortality 
rates for the various scoring systems
Variable  Actual mortality  Predicted mortality  SMR
APACHE II  0.244  0.296  0.824
APACHE IV  0.244  0.206  1.18
SAPS II  0.244  0.297  0.822
SAPS III  0.244  0.249  0.98
MPM II0 0.244  0.314  0.777
MPM III0  0.244  0.216 1.13
Table 2 (abstract P14). Area under the curve for predicting ICU mortality for 
various scoring systems
Scoring      Sensitivity  Specifi  city
system AUC  95%  CI  Cut-off    (%)  (%)
APACHE II  0.880  0.845 to 0.914  >18.5  86.9  75.8
APACHE III  0.880  0.847 to 0.914  >63.5  82.2  70.4
APACHE IV  0.882  0.848 to 0.916  >17.7  83.2  74
SAPS II  0.849  0.808 to 0.890  >41.5  82.2  70.4
SAPS III  0.873  0.838 to 0.907  >53.5  85  72.2
MPM II0  0.849  0.807 to 0.891  >30.1  77.6  76.1
MPM III0  0.872  0.835 to 0.909  >18.7  81.3  77.9
SOFA  0.889  0.857 to 0.922  >5.5  86.9  79.2
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patients was 64.5 ± 16.3 years and 301 (68.7%) were male. The mean 
ICU and hospital length of stay was 6.39 ± 9.7 and 9.99 ± 10.5 days, 
respectively. The observed ICU mortality was 107/438 (24.4%). Mortality 
predicted by SAPS III score was closest to that of actual mortality with 
a SMR of 0.98 followed by that of MPM III0 (SMR – 1.13) and APACHE IV 
(SMR – 1.18) scores (Table 1). APACHE IV (χ2 = 4.416; P = 0.818) had the 
best calibration followed by SAPS II (χ2 = 6.073; P = 0.639) and SAPS 
III scores (χ2 = 6.538; P = 0.587). There was no statistically signifi  cant 
diff  erence between the AUROCs of these scores; SOFA (AUROC = 0. 
0.889) performed the best followed closely by APACHE IV (AUROC = 
0.882) and APACHE III (AUROC = 0.880) scores (Table 2).
Conclusion Overall, the newer generation of scoring systems performed 
better than their older counterparts and was more accurate. Older 
scoring systems had a tendency to overpredict mortality. However, all 
the scores tested had good effi   cacy and the diff  erence in effi   cacy was 
not statistically signifi  cant.
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Introduction  The aim was to study the impact of infl  ammation/
sepsis on the concentrations of cystatin-C and neutrophil gelatinase-
associated lipocalin (NGAL) in plasma and urine in adult ICU patients 
and to estimate the predictive properties of cystatin-C and NGAL in 
plasma and urine for early detection of acute kidney injury (AKI) in 
patients with sepsis.
Methods The RIFLE class for AKI was calculated daily, while plasma and 
urinary Cys-C and NGAL were determined on days 0 and alternate days 
until ICU discharge. Test characteristics were calculated to assess the 
diagnostic performance of urinary and plasma Cys-C and NGAL. The 
diagnostic and predictive performances of the markers were assessed 
from the area under the receiver operator characteristic curve (AUC).
Results  One hundred and twenty-eight patients were studied, and 
three groups were defi  ned: normal (n = 41); sepsis (n = 45); and sepsis 
and AKI (n = 42). AUCs for diagnosis of AKI using plasma and uCys-C 
were as follows: 0.89 (P <0.0001) and 0.91 (P <0.0001) Cut-off   points for 
AKI for plasma and uCys-C were 1.7 mg/l (sensitivity: 83%, specifi  city: 
77%)and 0.11 mg/l (sensitivity = 92%, specifi  city = 80%), respectively. 
Urinary NGAL showed fair discrimination for AKI diagnosis (AUC = 0.85). 
Although plasma NGAL performed less well (AUC = 0.58).
Conclusion Plasma and urinary Cys-C are useful markers in predicting 
AKI in sepsis. pNGAL is raised in patients with sepsis, and should be 
used with caution as a marker of AKI in ICU patients with sepsis. uNGAL 
is more useful in predicting AKI as the levels are not elevated in septic 
patients without AKI.
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Introduction Sodium selenite (Na2SeO3) has been proposed as an 
early treatment of septic shock with discrepant results [1-3]. Benefi  cial 
action is mainly believed through improvement of major antioxidant 
selenoenzymes, but could on the contrary be related to a therapeutic 
oxidant action reducing activity of hyperactivated circulating 
phagocytic cells [4]. It has been suggested that the absence of benefi  cial 
eff  ect of high-dose Na2SeO3 continuously administered [2] might be 
related to toxicity, especially on the lung, of too much selenium (Se) as 
mentioned in recent parenteral nutrition guidelines in intensive care 
[5]. On additional clinical and biological data, our purpose was to assess 
if there was argument for Na2SeO3 toxicity, especially on the lung, under 
continuous administration of high-dose Na2SeO3 in the SERENITE study.
Methods In a randomized, double-blind multicenter study performed 
in 60 septic shock patients [2], the effi   cacy and tolerance of Na2SeO3 
(4 mg Se on day 1 (D1), then 1 mg/day during 9 days or placebo) 
were evaluated on all components of the SOFA score measured daily, 
infection rate, and plasma Se, selenoprotein-P (Sel-P), glutathione 
peroxidase (GPx), lipid peroxidation, cytokines, and procalcitonin 
measured at D0, D4, D7, D10 and D14.
Results No deleterious eff  ect of Na2SeO3 especially on the lung was 
observed for any clinical or biological variables. PaO2/FiO2 was strictly 
identical between groups (Table 1). As compared with placebo, mean 
time occurrences of infections were delayed in the treated group (18 ± 
24 days vs. 34 ± 28 days, respectively; P <0.0001). Plasma Se, Sel-P and 
GPx concentrations were increased at D4 in the treated group, achieving 
the high reference value for the plasma Se concentration (Figure 1).
Conclusion Continuous administration of high doses of Na2SeO3 (4 mg 
Se D1) did not induce any deleterious eff  ect in septic shock patients. 
We did not observe a benefi  cial eff  ect, contrasting with a comparable 
study administering Na2SeO3 in bolus, potentially more toxic [1]. In 
agreement with results obtained on a peritonitis sheep model [6], our 
data support a therapeutic oxidant action of Na2SeO3, opening a new 
fi  eld in septic shock treatment based on oxidant selenocompounds.
Table 1 (abstract P16). PaO2/FiO2 according to group and time
 Baseline
  (D0)  D2 D3 D4 D7  D10  D14
Na2SeO3  20 ± 15  23 ± 12  24 ± 10  25 ± 14  26 ± 11  30 ± 13  28 ± 15
Placebo   22 ± 13  21 ± 11  25 ± 13  26 ± 11  28 ± 14  33 ± 17  36 ± 17
P value 0.60  0.37  0.92 0.81 0.65 0.52 0.13
Data presented as mean ± SD (KPa).
Figure 1 (abstract P16). Plasma Se concentration according to groups and time. Data presented as mean ± SD (μmol/l). Reference value for plasma Se 
concentration: 1 ± 0.15 μmol/l. Treated group indicated in blue and nontreated in green.
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Introduction  The use of pharmacological and physical antipyretic 
therapies to reduce fever in febrile patients is common in hospital 
settings. Actual evidence on the frequency of antipyretic use is 
limited, however, both in general hospital populations and, more 
specifi  cally, in adult intensive care [1-3]. We undertook a prospective 
point prevalence study with the aim of identifying the prevalence of 
physical and pharmacological antipyretic therapies in intensive care 
patients with sepsis and infl  ammation. We also recorded the indication 
for antipyretic therapies, temperature measurement site, and mean 
temperatures on the study day.
Methods We conducted a single-day observational point prevalence 
study in 38 ICUs in Australia and New Zealand. All patients in participating 
ICUs at a 10:00 am census point were studied. Data were collected for the 
24-hour study day that included the 10:00 am time point.
Results  We studied 506 patients, with a mean age 59 years (SD = 
17 years); 65% male; APACHE II score 17 (SD = 7), 28-day mortality 
14%. Eighty percent of the ICU admissions were unplanned. Of the 
506 patients, 311 patients had sepsis and infl  ammation with mean 
peak temperature of 37.3°C (SD = 0.8°C). Of these, 35% (n = 100/311) 
had a mean peak temperature above 38°C. In the 24-hour period, 
paracetamol was used 50% (n = 152/311) of the time, nonsteroidal 
anti-infl   ammatory drugs (NSAIDs) 0.6% (n = 2/311) and physical 
cooling 1% (n = 3/311) (Figure 1). Of patients that had an indication for 
paracetamol recorded, 64% was for pain (n = 92/152), 18% for both pain 
and fever (n = 26/152); and 10% for fever alone (n = 14/152) (Figure  2). 
Sixty-four percent (n = 92/152) of the patients who had paracetamol 
were prescribed regular paracetamol and 36% (n = 51/143) had a PRN 
order. Of the 40 patients who received paracetamol for an indication of 
fever, the mean peak temperature was 38.3°C (SD = 0.8°C; range 36.1 
to 40.2°C). Of the three patients who received physical cooling, the 
mean peak temperature was 39.2°C (SD = 0.9°C; range 38.5 to 40.2°C). 
Temperature measurement sites were mainly noncore (n = 251/311) 
with axillary (37%; n = 116/311) and tympanic (35%; n = 110/311) most 
common (Figure 3).
Conclusion This point prevalence study of intensive care patients with 
sepsis and infl  ammation identifi  ed pharmacological antipyretics are 
used regularly for pain management rather than fever management, 
with paracetamol the most common therapy. The use of physical 
cooling was rare, and noncore temperature measurements were 
common. These results are important in understanding current 
temperature management practice in intensive care and will aid in 
designing future clinical trials on the subject.
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Introduction  Fever is a common observation during critical illness 
[1,2] and may be due to many possible causes such as infection, 
sterile infl   ammation and neurological injury. Clinical trials of fever 
management lack suffi     cient methodological quality to answer the 
question of whether attempts at reduction in temperature improves 
patient-centred outcomes in patients with sepsis, infl  ammation  or 
neurological injury [3-7]. We undertook a survey to describe the 
attitudes of critical care clinicians in Australia and New Zealand towards 
fever management in critically ill patients without neurological injury 
or hyperthermic syndromes.
Methods  An online scenario-based questionnaire survey was 
distributed to medical and nursing members of the Australian and New 
Zealand Intensive Care Society Clinical Trials Group (ANZICS-CTG) and 
their intensive care colleagues. Main outcome measures: the choice 
of drug and preferred threshold temperature for intervention with 
antipyretics in clinical practice and in a clinical trial.
Results  There were 588 email invitations distributed through the 
ANZICS-CTG and Research Coordinator mailing list. Four hundred and 
forty-seven responses were received from 308 nurses (69%), 137 doctors 
(31%), and two others (0.5%). The majority of respondents having 
more than 8 years of experience (62%) worked in mixed medical and 
surgical units (84%) in a metropolitan or tertiary hospital setting (77%). 
The primary fi  ndings of our survey suggest that fever management is 
highly variable. Most clinicians administer an intervention to reduce 
temperature at or below 39°C (Figure 1); and initially use a combination 
of both pharmacological and physical interventions, with an increase 
in intensity of physical interventions for persistent fever (Figure  2). 
There were diff   erences between the professions, with doctors 
choosing higher temperature thresholds for intervention and nurses 
generally using more physical cooling (Figure 1 and Table 1); fourthly, 
temperature thresholds for a clinical trial were 39.0°C (SD = 0.7°C) for a 
permissive strategy and 38.0°C (SD = 0.75°C) for an intensive strategy; 
fi  nally, there was broad support for a clinical trial of fever management.
Conclusion  This survey suggests there is considerable clinical 
variability in fever management in patients with sepsis and without 
neurological injury or hyperthermic syndromes. At present, no 
particular management strategy is known to be superior to any 
other and it remains possible that current practice may be harming 
substantial numbers of patients. A temperature threshold of up to 40°C 
may be acceptable to clinicians for the design of a future randomized 
controlled trial. Further observational data may be informative for the 
design of such clinical trials.
Figure 2 (abstract P17). Indication for paracetamol administration (n = 152).
Figure 3 (abstract P17). Temperature measurement site for patients with sepsis and infl  ammation (n = 311). PAC, pulmonary artery catheter.
Table 1 (abstract P18). Preference of fi  rst-line and second-line interventional 
category of antipyretic by profession
  First line (n = 418)  Second line (n = 409)
 Nurse  Doctor  P Nurse  Doctor  P
  (%)  (%) value (%)  (%) value
Pharmacological only  23  40  0.0002  5  5  0.87
Physical only  13  5  0.0087  58  62  0.36
Pharmacological and physical  64  55  0.077  38  33  0.39
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Introduction Sepsis is a life-threatening condition characterized by a 
whole-body infl  ammatory state. The early diagnosis and treatments 
of sepsis will improve the outcome of patients. The aim of this study 
was to compare blood levels of presepsin (renamed from soluble CD14 
subtype), procalcitonin (PCT), IL-6 and C-reactive protein (CRP) and to 
investigate the most useful biomarker for early diagnosis of sepsis.
Methods  A single-center, prospective, observational study. Patients 
who had one or more systemic infl   ammatory response syndrome 
criteria were included in this study. The blood samples for measuring 
the biomarkers were collected and the severity of sepsis was evaluated 
at the time of admission and every other day for a week. Forty-two 
patients were enrolled for the prospective study from June 2010 to 
December 2010.
Results  Twenty-three patients were diagnosed with sepsis and 19 
patients were without sepsis. In the receiver operating characteristics 
(ROC) curve analysis, the area under the curve (AUC) to distinguish 
sepsis was the largest for presepsin (0.930) followed by IL-6 (0.896), PCT 
(0.854) and CRP (0.840). Presepsin may be able to discriminate between 
patient groups with or without sepsis. From the ROC curve analysis, a 
cut-off   value of presepsin was 929 pg/ml with sensi  tivity and specifi  city 
of 76% and 81%, respectively, with odds ratios and 95% CIs of 0.996 
(0.992 to 0.998) and 3.376 (1.497 to 6.094). And the presepsin values 
were signifi  cantly higher in the patients with the more severe septic 
condition (for example, sepsis, severe sepsis, septic shock). In addition, 
a signifi  cant correlation was found between the Sepsis-related Organ 
Failure Assessment scores and the presepsin values (r2 = 0.320; P = 
0.0003). But there was a no signifi  cant correlation between APACHE II 
scores and the presepsin values.
Conclusion In this study, presepsin is the most valuable predictor about 
sepsis compared with PCT, IL-6 and CRP. Moreover, the results suggest 
that presepsin values can serve as a parameter that closely refl  ects the 
pathology. So we strongly suggest that the presepsin will be not only a 
very useful new biomarker of the diagnosis of sepsis, but also useful for 
monitoring the severity of the disease in the near future.
P20
An audit of awareness about maternal sepsis in a UK district general 
hospital
C Donohue, E Teh, M Kitching
Department of Anaesthesia, Lister Hospital, Stevenage, UK
Critical Care 2011, 15(Suppl 3):P20 (doi: 10.1186/cc10389)
Introduction The UK national body, which reviews maternal mortality 
(Centre for Maternal and Child Enquiries (CMACE)), has recently 
published their 2006 to 2008 report. This highlighted an increase in 
maternal sepsis, making it the leading cause of direct death amongst 
peripartum women in the UK (26 out of a total 107 direct deaths) 
[1]. The Surviving Sepsis Campaign (SSC) published updated sepsis 
resuscitation and management bundles in 2008 [2]. We decided to 
audit awareness about sepsis amongst staff    caring for perpartum 
women.
Methods A questionnaire was devised and distributed to midwives, 
obstetricians and anaesthetists. This asked the criteria for the systemic 
infl  ammatory response syndrome (SIRS), common sites of maternal 
sepsis, the initial duties of care (‘sepsis six’ resuscitation bundle: 
delivery of oxygen, intravenous fl  uids, intravenous antibiotics, taking 
of blood cultures, measurement of plasma haemoglobin, lactate and 
urine output) and recognition and management of severe sepsis.
Results There was a 98% response rate with 41 completed question-
naires returned, 15 from midwives, 13 from obstetricians and 13 from 
anaesthetists. We found that awareness was suboptimal within all 
groups. Of the six criteria for SIRS, suggested by the SSC, two criteria 
(altered consciousness and hyperglycaemia) were poorly identifi  ed 
and few responders were aware that two or more criteria indicated SIRS 
(Figure 1). Most healthcare professionals correctly identifi  ed genital 
tract infection as the leading source of maternal sepsis. The majority 
of responders had not heard of the ‘sepsis six’ (Figure 2). Out of the 
initial duties of care, delivery of oxygen and monitoring urine output 
were poorly identifi  ed. Respondents were not confi  dent in identifying 
features of severe sepsis and with the exception of hypotension despite 
fl  uids, other markers of end organ dysfunction were underreported.
Conclusion It is all of our responsibilities to focus eff  orts on the emerging 
threat of maternal sepsis as highlighted by CMACE. Historically, we 
have seen a signifi  cant improvement in maternal mortality rates when 
specifi  c interventions have targeted those issues raised in previous 
Figure 1 (abstract P18). Thresholds for initiation of antipyretic 
interventions between professions. Nurse/other (n = 289); doctor 
(n = 134) (P <0.0001).
Figure 2 (abstract P18). First-line and second-line treatment preferences 
for fever management (n = 458).
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propose to develop local clinical guidelines, posters and factsheets with 
formal teaching sessions and multidisciplinary simulator workshops 
to raise awareness, optimise care and minimise preventable deaths 
from maternal sepsis. We will re-audit awareness in 6 months time to 
complete the audit cycle.
References
1.  Cantwell R, Clutton-Brock T, Cooper G, et al.: Saving mothers lives: reviewing 
maternal deaths to make motherhood safer: 2006–2008. The Eighth 
Report of the Confi  dential Enquiries into Maternal Deaths in the United 
Kingdom. BJOG 2011, 118(Suppl 1):1-203.
2.  Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, 
Angus DC, Brun-Buisson C, Beale R, et al.: Surviving sepsis campaign: 
international guidelines for management of severe sepsis and septic 
shock: 2008. Crit Care Med 2008, 36:296-327.
P21
Septic shock and vasopressor requirement is associated with lower 
vitamin D levels in critically ill children
K Madden1,2, HA Feldman3,4,5, E Smith1, CM Gordon3,5,6, S Keisling1, 
R Sullivan1, BW Hollis7, AA Agan1, AG Randolph1,2
1Department of Anesthesia, Children’s Hospital Boston, MA, USA; 2Department 
of Anaesthesia, Harvard Medical School, Boston, MA, USA; 3Division of 
Endocrinology, Children’s Hospital Boston, MA, USA; 4The Clinical Research 
Program, Children’s Hospital Boston, MA, USA; 5Department of Pediatrics, 
Harvard Medical School, Boston, MA, USA; 6Division of Adolescent and 
Young Adult Medicine, Children’s Hospital Boston, MA, USA; 7Department of 
Pediatrics, Medical University of South Carolina, Charleston, SC, USA
Critical Care 2011, 15(Suppl 3):P21 (doi: 10.1186/cc10390)
Introduction Vitamin D plays an important role in immune and 
cardiovascular function. There is evidence that low 25-hydroxyvitamin 
D (25(OH)D) levels are associated with an increased risk of life-
threatening infections [1,2]. Our objective was to determine the 
prevalence of 25(OH)D defi  ciency (<20 ng/ml) in critically ill children 
and to identify any association with illness severity and infection.
Methods From November 2009 to November 2010, we collected blood 
samples and clinical data on children (<21 years old) near the time of 
admission to the pediatric ICU, excluding those admitted for short-
term monitoring. We measured plasma 25(OH)D concentrations in 
plasma using Diasorin radioimmunoassay on all subjects. Vasopressor 
requirement was measured using the cardiovascular component of the 
Sequential Organ Failure Assessment (CV-SOFA) score.
Results Among 511/818 (62.5%) eligible children, 40.1% were 25(OH)D 
defi  cient (median level 22.5 ng/ml (IQR = 16.4, 31.3)). Children with 
a confi  rmed (n = 144, 28.2%) or suspected (n = 94, 18.1%) diagnosis 
of infection on admission did not have lower 25(OH)D levels overall, 
except for those presenting in severe septic shock (n = 51, median = 
19.2 ng/ml, IQR = 12.6, 24.8; P = 0.0008). In the multivariate analysis, 
older age and nonwhite race were associated with vitamin D defi  ciency 
while summer season, vitamin D supplementation and formula intake 
were strongly protective. Patients with higher pediatric ICU admission 
day illness severity by PRISM-III score quartiles had lower vitamin 
D levels (OR = 1.19 per 5 ng/ml decrease in 25(OH)D, 95% CI = 1.10, 
1.28, P <0.0001) after adjusting for risk factors. When septic shock was 
added to this model, there was no eff  ect on the association between 
25(OH)D level and PRISM-III quartile (OR = 1.18 (95% CI = 1.09, 1.27, 
P <0.0001)). There was also an inverse association between 25(OH)D 
level and maximal vasopressor use as measured by the CV-SOFA score 
in a multinomial regression model (OR = 1.13, 95% CI = 1.01, 1.27, P = 
0.03). Including septic shock in the multivariable model did not aff  ect 
the eff  ect of vitamin D level (OR = 1.16, 95% CI = 1.02, 1.31, P = 0.02)) 
on CV-SOFA score.
Conclusion The overall prevalence of vitamin D defi  ciency in critically ill 
children is high, and patients with severe septic shock had signifi  cantly 
lower vitamin D levels than the general population. This association 
between vitamin D and septic shock may be due to the cardiovascular 
eff  ects of vitamin D or to increased severity of infection with diminished 
25(OH)D levels. These results suggest a role for the vitamin D axis in 
sepsis and hemodynamic instability that deserves further investigation.
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Introduction  The endothelial glycocalyx is a recently discovered 
structure at the luminal side of blood vessels consisting of proteo-
glycans and glycosaminoglycans, which play an important role in 
vascular barrier function and cell adhesion. Due to its vulnerability, the 
endothelial glycocalyx may easily be altered by hypoxia [1], TNFα [2], 
oxidized lipoproteins [3] and other nonphysiological conditions. We 
raised the question of whether the glycocalyx may be shed from the 
endothelium in dependence of severity of sepsis.
Methods This clinical prospective study – approved by the local ethics 
committee – was performed to assess plasma levels of the glycocalyx 
components (hyaluronane, syndecan, heparan sulfate) by ELISA 
technique and polymorphonuclear leukocyte (PMN) function by fl  ow 
cytometry in eight healthy volunteers (HV) and 37 patients who were 
prospectively enrolled within 24 hours of onset of signs of infection, 
if they met the criteria for sepsis (n = 10), severe sepsis (n = 9) and 
septic shock (n = 18) as defi  ned by the members of the ACCP/SCCM 
Consensus Conference Committee (Table 1). Blood was drawn within 
Figure 1 (abstract P20).
Figure 2 (abstract P20).
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patients or their legal representatives, respectively.
Results Plasma levels of the glycocalyx components were signifi  cantly 
higher in septic patients than in healthy volunteers and even more 
pronounced in patients with severe sepsis and septic shock (all P <0.05; 
Figure 1). Hyaluronan and syndecan plasma levels correlated positively 
with the APACHE II, SOFA and MOD scores (Figure 1 and Table 2). 
Hyaluronan displayed a positive correlation with the C-reactive protein, 
procalcitonin and IL-6 in plasma (Table 3). The PMN dysfunction – 
characterized by an increase in cytotoxic capability and a decrease in 
microbicidity – showed a parallel course to the heparan sulfate plasma 
levels.
Conclusion  Elevated plasma levels of hyaluronan, syndecan and 
heparan sulfate are suggestive of a glycocalyx shedding from 
endothelium with increasing sepsis severity. This process might 
contribute to the vascular dysfunction and development of edema in 
septic patients.
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Figure 1 (abstract P22). (a) to (c) Increase in the glycocalyx components in plasma of healthy volunteers (HV) and of patients with increasing sepsis severity. 
(d) Correlation between APACHE II score of septic patients and hyaluronan plasma concentrations.
Table 1 (abstract P22). Demographic data
 Healthy    Severe  Septic
 volunteers  Sepsis  sepsis  shock
 ( n = 8)  (n = 10)  (n = 9)  (n = 18)
Age (years)  29.1 ± 2.9  51.6 ± 19.7  63.3 ± 23.5  63.3 ± 21.4
APACHE II  n.b.  7.6 ± 3.9  17.8 ± 6.9  27.9 ± 5.3
MOD  n.b.  2.1 ± 1.6  6.9 ± 3.2  9.4 ± 3.6
SOFA  n.b.  4.1 ± 2.8  9.0 ± 3.0  13.3 ± 3.4
Table 2 (abstract P22). Correlation between the glycocalyx components 
(hyaluronan, syndecan) and the APACHE II, SOFA and MOD score of septic 
patients
 APACHE  II  SOFA  MOD
Hyaluronan  r2 = 0.583,   r2 = 0.529,   r2 = 0.435, 
  P = 0.000  P = 0.001  P = 0.008
Syndecan  r2 = 0.425,   r2 =0.476,   r2 = 0.529, 
  P = 0.010  P = 0.003  P = 0.001
Table 3 (abstract P22). Correlation between the glycocalyx components 
(heparan sulfate, hyaluronan) and the C-reactive protein, procalcitonin and 
IL-6 in plasma of septic patients
 CRP  PCT  IL-6
Heparan sulfate  r2 = –0.63,   r2 = 0.20,   r2 = 0.505, 
  P = 0.714  P = 0.928  P = 0.012
Hyaluronan  r2 = 0.398,   r2 = 0.723,   r2 = 0.468, 
  P = 0.016  P = 0.000  P = 0.021
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Introduction  The febrile response in the context of infection may 
be linked to a protective host response through enhanced immune 
function at elevated body temperatures [1-9]. Alternatively the use 
of antipyretics may reduce metabolic expense, patient discomfort, or 
protect against neurological injury.
Objective To determine whether fever is associated with reduced risk 
of death in patients admitted to an ICU with infection compared with 
other patients.
Methods A retrospective cohort study using a database of Australian 
and New Zealand (ANZ) ICU admissions as a development cohort and 
a database of UK ICU admissions as a validation cohort. The sample 
included 129 ICUs in ANZ and 201 ICUs in the UK. The ANZ development 
cohort consisted of 269,078 patients and the UK validation cohort 
consisted of 366,973 patients. All patients were admitted to an ICU 
between 2005 and 2009. A total of 29,083/269,078 (10.8%) ANZ patients 
and 103,191/366,973 (28.1%) UK patients were categorised as having 
an infection at the time of ICU admission. The main outcome measures 
were the association between peak temperature in the fi  rst 24 hours 
after ICU admission and in-hospital mortality in patients admitted with 
or without infection.
Results  In the ANZ cohort, adjusted in-hospital mortality risk 
progressively decreased with increasing peak temperature in patients 
with infection. Relative to 36.5 to 36.9°C, the lowest risk was at 39 to 
39.4°C (adjusted OR = 0.56; 95% CI = 0.48 to 0.66). In patients without 
infection, the adjusted mortality risk progressively increased above 
39.0°C (adjusted OR = 2.07 at ≥40.0°C; 95% CI = 1.68 to 2.55). In the UK 
cohort, fi  ndings were similar with adjusted odds ratios at corresponding 
temperatures of 0.77 (95% CI = 0.71 to 0.85) and 1.94 (95% CI = 1.60 
to 2.34) for the infection and non-infection groups, respectively. See 
Figures 1 and 2.
Conclusion  Peak temperature in the fi   rst 24 hours in the ICU is 
associated with decreased in-hospital mortality in critically ill patients 
with an infection; randomised trials are needed to compare the eff  ect 
on mortality of controlling fever against a permissive approach to fever 
management in such patients.
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Figure 1 (abstract P24). Adjusted* odds ratios for in-hospital mortality 
versus peak temperature in the fi  rst 24 hours in the ICU for patients in 
the infection group. *Odds ratios adjusted for illness severity using the 
ICNARC (2009) model predicted log odds of acute hospital mortality with 
the temperature component removed for the UK data and the APACHE 
III predicted log odds risk of death with the temperature component 
removed for the ANZ data.
Figure 2 (abstract P24). Adjusted* odds ratios for in-hospital mortality 
versus peak temperature in the fi  rst 24 hours in the ICU for patients in the 
non-infection group. *Odds ratios adjusted for illness severity using the 
ICNARC (2009) model predicted log odds of acute hospital mortality with 
the temperature component removed for the UK data and the APACHE 
III predicted log odds risk of death with the temperature component 
removed for the ANZ data.
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Introduction  Sepsis is the most common cause of morbidity and 
mortality in ICU patients. The clinical signs of infection and routine 
laboratory tests are not specifi  c and at times misleading. Even the 
bacteriological evidence of infection is not sensitive enough. In view 
of this diagnostic and therapeutic dilemma, an eff  ective and specifi  c 
marker is needed that can support or exclude the diagnosis of infection. 
Hence we evaluated the usefulness of biochemical markers such as 
procalcitonin (PCT) and high-sensitivity C reactive protein (hsCRP) in 
monitoring the therapeutic response to treatment in patients with 
sepsis.
Methods Fifty-seven patients admitted to the ICU of Sir Ganga Ram 
Hospital, New Delhi, India from July 2010 to April 2011 with a fresh 
episode of sepsis were included in the study. PCT and hsCRP were 
analyzed in serum samples at 0 hours, 24 hours and 72 hours. Blood 
cultures were performed on the day of admission (0 hours) and the 
patients were categorized as culture positive or culture negative. 
Patients were followed up for 28 days and were then grouped as 
survivors and nonsurvivors.
Results During the observation period of 28 days, 44 patients survived 
and 13 expired. Over a period of 0 to 72 hours the PCT level decreased in 
86% survivors as compared with 46% nonsurvivors (P =0.001), whereas 
it increased in 13.6% survivors as compared with 53.8% nonsurvivors 
(P = 0.001). The change in the levels of hsCRP in both surviving and 
nonsurviving patients was not signifi  cant. The 0-hour blood culture 
was positive in 24 out of 57 patients. The PCT levels at 0 hours was 
signifi  cantly high in culture-positive patients (P = 0.002) as compared 
with culture-negative patients, whereas there was no signifi  cant 
diff  erence in the hsCRP levels in the above-mentioned groups. The 
area under the curve of PCT and hsCRP in culture-positive and culture-
negative patients was 0.743 (95% CI = 0.608 to 0.878, P = 0.002) and 
0.564 (95% CI = 0.414 to 0.715, P = 0.405), respectively.
Conclusion These observations indicate that PCT is a better prognostic 
indicator than hsCRP and is also a better predictor of bacteremia in the 
newly admitted critically ill patients of sepsis. Hence, routine use of PCT 
as a monitoring tool may aid in appropriate therapeutic intervention in 
patients with sepsis.
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Introduction Over the past several years, the early identifi  cation and 
aggressive treatment of sepsis patients has become a standard of care 
in the hospital setting. A relatively small number of emergency medical 
service (EMS) systems have started programs to screen for sepsis; an 
even smaller number provide treatment based on that screening 
process in the prehospital setting.
Objective The purpose of this study is twofold. First, the study aims 
to determine how eff  ectively paramedics working in the county EMS 
system can use a screening tool to identify potential sepsis patients 
and provide an alert to the receiving hospital. Second, the study will 
examine whether or not an early identifi  cation process in the fi  eld leads 
to improved treatment of sepsis. The end goal is to reduce morbidity 
and mortality of sepsis patients in the hospital setting.
Methods  This is a multi-site prospective observational study with 
comparison to retrospective cohort. Patient data will be collected to 
determine whether or not the alert process leads to early obtaining of 
a serum lactate measurement and early goal-directed therapy.
Results  Data points being analyzed from prehospital care reports: 
criteria from the sepsis screening tool include evidence of infection, 
temperature, heart rate, respiratory rate; and EMS fi  eld  clinical 
impression (for comparison with emergency department (ED) 
admitting diagnosis). Data points being analyzed in the hospitals 
include the following: ED admitting diagnosis; serum lactate values, 
blood culture, timestamps; evidence of early goal-directed therapy – 
timestamps/values for fl   uid and antibiotic administration; hospital 
admitting diagnosis; and discharge diagnosis. The results of the study 
will be available by 2012/2013.
Conclusion Preliminary anecdotal and early data analysis reports from 
EMS and hospital staff   suggest that patients are being identifi  ed as 
septic prior to ED arrival and have lower lactate levels. Patients are also 
treated more timely on arrival to the ED for sepsis. Final data analysis 
will shed more light on our hypothesis. Early identifi  cation of septic 
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Introduction  Despite extensive research in the fi   eld of sepsis 
pathogenesis and its management, mortality associated with sepsis in 
hospitals remains very high. For example, more than 18 million people 
are aff  ected by sepsis worldwide and have an expected 1% increase 
annually in ICUs. Sepsis is the outcome of a deregulated immune 
system occurring during systemic bacterial (that is, Gram-negative or 
Gram-positive) infection. So modulating the immune system by an 
immunomodulatory approach may prove benefi  cial to sepsis patients. 
In the present study, we evaluated the protective immunomodulatory 
eff  ect of thalidomide alone or with augmentin in Klebsiella pneumoniae 
B5055-induced sepsis in BALB/c mice.
Methods  The mouse model of sepsis was developed by placing 
K.   pneumoniae B5055 entrapped in fi   brin and thrombin clots in 
the peritoneal cavity of mice. The septic mice were treated with 
thalidomide alone (30 mg/kg/day p.o.), with augmentin alone 
(20 μg/ml i.p.) and with their combination. The bacterial load in blood 
was estimated by blood culture on MacConkey’s agar plates along with 
measuring the other systemic infl  ammatory parameters. For example, 
lipid peroxidation was measured in terms of malondialdehyde (MDA) 
and nitric oxide (NO) levels in serum by biochemical methods. Levels 
of proinfl   ammatory cytokines (that is, TNFα and IL-1α) and anti-
infl  ammatory cytokine (that is, IL-10) levels in serum were measured 
by ELISA.
Results  The thalidomide-alone-treated mice showed 75% survival 
whereas 60% of the augmentin-alone-treated group survived. 
However, their combination (thalidomide + augmentin) treatment 
provided 100% survival. Treatment with thalidomide alone signifi  cantly 
(P <0.05) decreased TNFα, IL-1α, NO and MDA levels in the serum 
without signifi  cantly  (P <0.05) decreasing the bacterial count in 
blood. However, levels of IL-10 in serum were found to be signifi  cantly 
(P <0.05) elevated upon thalidomide treatment. Augmentin alone only 
decreased the bacterial load in blood signifi  cantly (P <0.05), while no 
signifi  cant decrease was observed on infl  ammatory mediators studied. 
However, a combination thalidomide with augmentin signifi  cantly 
(P <0.05) decreased both the bacterial count as well as infl  ammatory 
mediators (that is, TNFα, IL-1α, NO and MDA) and provided 100% 
protection to animals.
Conclusion Thalidomide can be used as an immunomodulatory agent 
along with antibiotics for sepsis management.
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vasoreactivity to noradrenaline in a rat endotoxaemia model
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Introduction  In septic shock, iNOS activation and nitric oxide (NO) 
overproduction contribute to vascular hyporeactivity to adrenergic 
vasopressors. The consequent hypotension often necessitates high 
doses of catecholamine administration. However, this may lead to 
detrimental eff  ects on tissue perfusion, immune function and myo-
cardial function. Asymmetric dimethlyarginine (ADMA), an endo  ge  nous 
inhibitor of NO synthase, is extensively metabolised by dimethylarginine 
dimethylaminohydrolase (DDAH). Competitive inhi  bi  tion of the DDAH-1 
isoform should thus reverse hypotension but, as this isoform is absent 
in immune cells, it should not compromise the immune eff  ects of NO. 
Hence, we investigated whether L257, a novel DDAH-1 inhibitor, could 
spare norepinephrine dosing in a rat endotoxic shock model.
Methods  Anaesthetised, spontaneously breathing male Wistar rats 
(body weight 270 to 330 g) had their left carotid artery and right 
internal jugular vein cannulated for arterial pressure monitoring and 
fl   uid infusion, respectively. Then 40 mg/kg Klebsiella pneumoniae 
lipopolysaccharide was administered intravenously over 30 minutes 
followed by fl  uid resuscitation at a rate of 10 ml/kg/hour thereafter. 
When the mean arterial pressure fell over 20% below baseline, they 
received norepinephrine titrated to maintain arterial pressure at ±10% 
baseline. Thirty minutes post commencement of norepinephrine, 
animals were randomized to receive either L-257 (3 mg/kg bolus 
then infusion of 125 μg/hour) or, in controls, an equivalent volume 
of saline. Experiments were terminated 3 hours post commencement 
of norepinephrine titration, before which echocardiography was 
performed and serum samples were collected for biochemistry.
Results L-257-treated animals (n = 8) required a signifi  cantly lower total 
dose of noradrenaline over 3 hours compared with the eight control 
animals (38 ± 9 vs. 48 ± 4 μg, P <0.05). The heart rate was signifi  cantly 
lower in the treatment group (P <0.05), which associated with a trend 
of increased stroke volume and cardiac output. Serum BUN and urea 
were also signifi  cantly lower in the treatment group (P <0.05, Table 1).
Conclusion In this acute endotoxic rat model, we demonstrate that 
DDAH-1 inhibition by L-257 could reduce norepinephrine dosage and 
ameliorate its harmful eff  ects. This agent warrants further study as a 
putative therapy for septic shock.
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P30
A novel DDAH-1 inhibitor improved cardiovascular function in a 
short-term anesthetized rat model of sepsis
Z Wang, V Taylor, R Stidwill, J Leiper, M Singer
Bloomsbury Institute of Intensive Care Medicine, Department of Medicine, 
University College London, UK
Critical Care 2011, 15(Suppl 3):P30 (doi: 10.1186/cc10399)
Introduction  Excessive NOS activity and NO overproduction are 
believed to play an important role in sepsis-induced macrocirculatory 
and microcirculatory dysfunction. Asymmetric dimethylarginine 
(ADMA), an endogenous inhibitor of NO synthesis, is extensively 
metabolised by dimethylarginine dimethylaminohydrolase (DDAH). 
Table 1 (abstract P29).
Variable  NE  NE + L-257  P value
SV (ml/minute)  0.18 ± 0.04  0.23 ± 0.04  0.07
HR (beats/minute)  500 ± 15  449 ± 37  0.03
CO (ml)  90 ± 18  102 ± 19  0.31
U (mM)  16.6 ± 1.2  12.8 ± 1.7  0.01
BUN (mg/dl)  44.8 ± 3.7  35.9 ± 4.8  0.03
Cr (μM)  51.3 ± 15.2  31.8 ± 4.3  0.08
ALT (IU/l)  98 ± 79.8  71.3 ± 48.3  0.6
Figure 1 (abstract P30). (a) The eff  ect of bolus doses of L-257 at 0 mg/kg, 3 mg/kg, 30 mg/kg and 300 mg/kg on the mean arterial pressure in the short-
term organ function study on anaesthetized Wistar rats (n = 6 in the each group). The bolus L-257 was given at 0 minutes for 10-minute infusion. Animals 
treated with 300 mg/kg L-257, ×; animals treated with 30 mg/kg L-257, open triangle; animals treated with 3 mg/kg, open square; control animals, solid circle. 
(b) The initial change of mean arterial pressure 30 minutes after bolus injections among the four groups. *P <0.05, 30 mg/kg vs. control; #P <0.05, 30 mg/kg 
vs. 3 mg/kg; †P <0.05, 300 mg/kg vs. control; ‡P <0.05, 300 mg/kg vs. 3 m/kg. (c), (d) The eff  ects of bolus doses of L-257 at 0 mg/kg, 3 mg/kg and 30 mg/kg on 
perfused capillary density and microcirculatory index (n = 4 in each group). *P <0.05, 30 mg/kg vs. control; #P <0.05, 30 mg/kg vs. 3 m/kg.
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inhibition should theoretically reverse sepsis-induced hypotension. We 
thus investigated the dose-dependent cardiovascular eff  ects of a novel 
DDAH-1 competitive inhibitor, L-257, in experimental sepsis.
Methods  Anaesthetised, spontaneously breathing male Wistar rats 
(body weight 270 to 330 g) had their left carotid artery and right 
internal jugular vein cannulated for arterial pressure monitoring and 
fl   uid infusion, respectively. Then 40 mg/kg Klebsiella pneumoniae 
lipopolysaccharide was administered intravenously over 30 minutes 
followed by fl  uid resuscitation at a rate of 10 ml/kg/hour thereafter. 
When the mean arterial pressure fell over 20% below baseline, groups 
(n = 6) were randomized to receive a bolus dose of L-257 of 0 (control), 
3, 30 or 300 mg/kg. Animals were sacrifi  ced 2 hours later with prior 
measurement of gastrocnemius muscle microcirculatory perfusion and 
with collection of plasma samples for biochemistry, arginine, ADMA 
and nitrate/nitrite measurements.
Results The bolus doses of L-257 were given after approximately 60 to 
90 minutes post endotoxin when the mean BP fell over 20%. Arterial 
pressure, perfused capillary density and microcirculatory fl  ow index were 
better maintained than in controls, especially at higher doses (Figure 1, 
P <0.05). Signifi  cantly higher plasma ADMA concentrations and ADMA/
arginine ratios were seen in the 30 mg/kg bolus group (Figure 2, P <0.05). 
Plasma nitrate/nitrite levels in the treated animals were signifi  cantly 
lower compared with those in controls (Figure 2, P <0.05).
Conclusion  In this short-term rat model of endotoxaemia, we 
demonstrated protective dose-dependent eff  ects of a novel DDAH-1 
inhibitor, L-257, on cardiovascular function. This was associated with an 
elevation of plasma ADMA level and a resultant reduction of plasma 
nitrate/nitrite level.
Acknowledgements This study was funded by Wellcome Trust in the UK.
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Introduction Sepsis remains a major and increasing healthcare problem 
with a mortality exceeding 25%. The early detection of infection is 
important in treating sepsis. Nucleic acid amplification methods have 
the potential to improve the timeliness, sensitivity, and accuracy of the 
tests used to detect respiratory pathogens. We used a quantitative real-
time PCR (rt-PCR) to detect the enteric bacterial counts in blood from 
patients in the emergency room.
Methods EDTA samples were collected from patients with systemic 
infl  ammatory response syndrome (SIRS) presenting to the emergency 
room after obtaining informed consent. Enteric bacterial loads in blood 
samples were assayed by rt-PCR to quantitate the bacterial 23S rDNA 
and EB rDNA loads. Descriptive and clinical data were collected from 
the medical records and compared with 23S and EB rDNA results.
Results  From January 2011 to April 2011, 39 patients (mean age 
71.15 ± 17.12, range 22 to 93) were enrolled in the study. There was no 
correlation between serum lactate and enteric bacterial load in patients 
with SIRS. However, in a subgroup comprising patients presenting with 
respiratory distress and abnormal blood white cell count, the enteric 
bacterial rDNA load was higher and showed correlation with serum 
lactate level. The serum enteric bacterial rDNA loads were signifi  cantly 
higher in patients with positive cultures and in patients presenting with 
higher serum lactate. Correlations between serum lactate and enteric 
bacterial rDNA load were also signifi  cant in the patients with positive 
culture results.
Conclusion The quantitative assay for enteric bacterial rDNA could be 
a useful tool to detect early enteric bacterial translocation in patients 
presenting to the emergency room with elevated serum lactate level or 
with respiratory distress and abnormal white blood cell counts.
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Direct eff  ects of esmolol, ultra-short-acting β-blockers, on cardiac 
function, ion channels, and coronary arteries in guinea pigs
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Introduction  β1-adrenergic antagonists have been recently used in 
septic patients to improve sepsis-induced immune, cardiovascular and 
coagulation dysfunction. But it is diffi   cult and one is hesitant to use 
these drugs in septic shock patients who have already had hypotension 
Figure 2 (abstract P30). The eff  ect of bolus doses of L-257 at 0 mg/kg, 3 mg/kg and 30 mg/kg on (a) plasma arginine and (b) ADMA concentrations, (c) the 
ADMA/arginine ratio and (d) plasma nitrate/nitrite concentrations in the short-term organ function study on anaesthetized Wistar rats (n = 6 in each group). 
*P <0.05, 30 mg/kg vs. control; #P <0.05, 30 mg/kg vs. 3 m/kg; †P <0.05, 3 mg/kg vs. control.
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direct eff  ects on heart function in addition to their β1 blocking eff  ects. 
Since little is known about their acute direct eff  ects on mammalian 
heart, we therefore evaluated the direct eff   ects of esmolol, ultra-
short-acting β-blockers, on cardiac performance and single cell-
electrophysiology in guinea pig hearts, and compared these eff  ects 
with those of landiolol.
Methods  All animal experiments were approved by the University 
Animal Ethics Committee. Under deep anesthesia with pentobarbital, 
the heart was excised and mounted on a Langendorff    apparatus 
to measure the coronary perfusion pressure (CPP). The saline-fi  lled 
balloon was inserted into the left ventricle to measure the heart rate 
(HR) and systolic left ventricular pressure (sLVP). The coronary fl  ow 
was maintained at a constant value during the experiments. Single 
ventricular cells were enzymatically isolated from hearts and cardiac 
ion currents were investigated by the patch clamp methods. Group 
comparisons were conducted by one-way repeated-measures analysis 
of variance with Dunnett’s or Turkey’s multiple comparison test. 
Diff  erences at P <0.05 were considered to denote signifi  cance.
Results Esmolol increased CPP in a concentration-dependent manner, 
and decreased both the sLVP and HR signifi  cantly at concentrations 
>10 μM. Esmolol also shortened the action potential duration (APD) in a 
concentration-dependent manner, and inhibited the inward rectifi  er K+ 
current (IK1), while the L-type Ca2+ current (ICaL) and outward current (IKs 
and IKr) and ATP-sensitive K+ current were hardly aff  ected. Furthermore, 
with the application of BAPTA from patch pipettes, the chelation 
of intracellular calcium ion did not antagonize APD shortening by 
esmolol. On the other hand, landiolol had minimal eff  ects on cardiac 
coronary perfusion, cardiac contractility, action potential, and cardiac 
ionic currents. In the Kyoto Model computer simulation, sole inhibition 
of IK1 or ICaL failed to simulate APD shortening induced by esmolol.
Conclusion  The present fi   ndings demonstrated that esmolol has 
more direct eff  ects on the heart than landiolol; that is, the elevation 
of coronary perfusion pressure and negative inotropic action. The 
negative inotropic action is accompanied with the APD shortening in 
single cardiomyocytes. Inhibition of IK1 and ICaL, and inhibition of ionic 
current systems other than those we identifi  ed may be involved in the 
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Introduction  Pulmonary fi   brosis is a major and common medical 
condition, characterized by progressive scaring and decline in lung 
function. Persistent infl  ammation and acute lung injury in response 
to sepsis are potential triggers of the fi   brotic response. Recently, 
we have reported that Escherichia coli sepsis in baboons strongly 
induces procoagulant responses and aff  ects the integrity of the lung. 
These eff  ects are diminished by the treatment with compstatin, a C3 
convertase complement inhibitor [1].
Methods Here we used the baboon model described [1] in conjunction 
with detailed gene expression analysis, as well as biochemical and 
histological assays to determine if E. coli sepsis triggered metabolic 
and signaling pathways related to lung remodeling and fi  brosis, and 
whether complement inhibition could attenuate these pathways.
Results  Microarray gene expression analysis shows that sepsis 
augments several fi  brotic gene clusters in the lung as early as 24 hours 
post  E. coli challenge. Immunochemical and biochemical analysis 
reveals enhanced collagen synthesis, induction of profi  brotic factors 
and increased cell recruitment and proliferation. Compstatin treatment 
decreases sepsis-induced expression of extracellular matrix genes, 
including eight collagen genes. Sirius Red and immunofl  uorescence 
staining for procollagens 1 and 3 confi  rms the collagen deposition in 
the lung. Ingenuity® pathway analysis of transcriptomics data shows 
that  compstatin treatment reduces sepsis-induced expression of 
genes involved in fi   broblast transformation and connective tissue 
production, cell chemotaxis, migration and proliferation (see Table 1). 
Immunocytochemistry and pathway-oriented transcriptomics and 
phospho-proteomics analysis reveal changes of multiple processes 
mediated by transforming growth factor beta (TGF-β), connective tissue 
growth factor and other TGF-β controlled proteins. Immunostaining 
for cell proliferation markers demonstrates that compstatin treatment 
strongly reduces cell proliferation in fi  broblastic  foci.  Moreover, 
biochemical analysis shows decreased production in the compstatin-
treated group of two chemokines responsible for fi  brocyte recruitment 
(CCL2 and CXCL12) and of the type 1 tissue inhibitor of metalloproteases 
that controls extracellular matrix remodeling.
Conclusion Our data demonstrate that bacterial sepsis initiates pulmonary 
collagen deposition, and complement inhibition eff  ectively attenuates the 
fi  brotic response. This suggests that complement inhibitors could be used 
for prevention of sepsis-induced pulmonary fi  brosis.
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Table 1 (abstract P34).
  E. coli  E. coli + CS T+5
 Modifi  ed genes  Modifi  ed genes
 Up  Down  Total  P value  Up  Down  Total  P value
Fibroblast transformation  32  10  42  1.41 x 10–6  12 69 81  1.09  x  10–7
Connective tissue disorder  133  59  192  2.62 x 10–5 92  341  434 3.1  x  10–7
Chemotaxis  39 13 52  5.0  x  10–3  31  92  123  1.98 x 10–5
Cell migration  95  40  135  2.11 x 10–5  80  250  330  9.36 x 10–8
Cell proliferation  187  70  257  2.67 x 10–8  118 466 584  5.83  x  10–13
Fibroblast proliferation  23  7  30  4.80 x 10–3  10 62 72  5.56  x  10–6
CS T+5, compstatin-treated animals at T + 5 hours.
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Introduction AB103 is a novel CD28 antagonist peptide currently in 
clinical development that modulates CD28 signaling in T cells, without 
aff   ecting the normal humoral immune response. In experimental 
models of Gram-positive, Gram-negative and polymicrobial sepsis, 
AB103 demonstrated signifi  cant activity, increasing overall survival.
Methods The AB103 activity and mode of action (MOA) were evaluated 
in a murine model of cecal ligation and puncture (CLP). AB103 (5 mg/kg) 
was administered to mice (Balb/c) at various times points following CLP 
(2 to 24 hours), together with moxifl  oxacin.
Results A single dose of AB103, given at 12 or 24 hours post CLP, rescued 
100% and 62.2% of the animals (respectively) from sepsis-induced 
mortality, whereas moxifl  oxacin alone (LD90, given at 12 hours) rescued 
only 25% (P <0.05) of the animals. In a separate set of experiments 
investigating the MOA, AB103 administration (5 mg/kg, given without 
antibiotics 2 hours post CLP) was associated with: a reduction in Th-1 
cytokine levels in peritoneum (TNFα, IL-3, IL-17 and Rantes) and plasma 
(IL-3 and IL-6); a reduction in splenocyte proliferation, stimulated ex 
vivo with anti-CD3 and anti-CD28 antibodies; a reduction in neutrophil 
recruitment to the spleen, liver and kidney, as determined by MPO 
activity; and a reduced bacterial load in peritoneum, blood and tissues 
(kidney, liver, spleen).
Conclusion These data demonstrate that attenuation of CD28 signaling 
is a viable therapeutic approach to the treatment of sepsis. Due to its 
robust activity and good safety profi  le in humans already established in 
a phase 1 study, AB103 should be clinically evaluated in sepsis patients.
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Introduction  In sepsis, sympathetic nerve activity is diff  erentially 
increased in individual organs. The increased cardiac sympathetic 
nerve activity is partly responsible for the increase in heart rate (HR) 
and cardiac output (CO) opposing the development of hypotension [1]. 
Recently, in a rat septic model, β-blockade appeared safe and decreased 
the infl  ammatory response and mortality [2]. Accordingly, we sought to 
investigate the cardiovascular eff  ects of selective β1-receptor blockade 
in a sheep model of sepsis.
Methods  Eight merino ewes were studied in a university-affi   liated 
research institute in Melbourne. The study design was a prospective 
interventional crossover animal study. The animals had renal and 
cardiac fl  ow probes implanted to continuously measure CO and renal 
blood fl  ow (RBF). Every animal was randomly allocated to receive sepsis 
and atenolol (atenolol group, AG) or sepsis alone (control group, CG) and 
then crossed over. After 24 hours of baseline period, sepsis was induced 
through a bolus of live Escherichia coli by a continuous infusion for a 
total 24 hours of sepsis. After the fi  rst 8 hours of sepsis (development 
sepsis period, DS), a bolus of atenolol (10 mg bolus) was given followed 
by a continuous infusion of 0.125 mg/kg/hours for 16 hours. Two-way 
repeated-measure ANOVA was performed to compare the average of 
periods and group interaction. P <0.05 was considered signifi  cant (not 
signifi  cant (NS), P >0.05).
Results Animals in the AG and CG had similar baseline values and 
developed a similar hyperdynamic state in the DS (Figure 1 and 
Table  1). Atenolol reduced CO and HR without changes in stroke 
volume. Hypotension was slightly greater in the AG than in the CG 
(MAP: 81.5 vs. 86.1 mmHg) with a greater decrease in total peripheral 
conductance (16.8 vs. 22.1 l/minute/mmHg). Changes in lactate level 
were similar. Similar increases in RBF and in renal vascular conductance 
(RVC) were observed in the AG and CG and after an initial increase in 
diuresis in the DS, oliguria similarly subsequently developed in both 
groups. Creatinine clearance decreased in a similar way in the AG and 
CG from 59.2 (± 2.8) to 32 (± 5.7) ml/minute and from 65.2 (± 9.9) to 
36 (± 7) ml/minute, respectively (P = 0.381). One animal in the AG and 
two in the CG died in the 24 hours after the end of sepsis.
Conclusion β-blockade in hyperdynamic sepsis appears safe. It results 
in only limited decreases in mean arterial pressure, and does not 
increase lactate levels or worsen renal function.
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Introduction  Previously our group has developed neural net 
progression models to characterize the development of organ failure 
in an ovine only as well as an integrated human/ovine model of acute 
lung injury using early clinical information. The goal of this study was 
to expand our model of disease progression using clinically available 
Table 1 (abstract P36). Hemodynamic and renal fi  ndings during baseline, 
development (DS) and intervention sepsis periods in the CG and AG groups
     Development  Sepsis 
   Baseline  sepsis  intervention 
 Group period  period  (DS)  period  P value
CO  CG  3.68 (0.29)   3.68 (0.29)  4.12 (0.29)  <0.001
  AG  3.21 (0.22)  3.21 (0.22)  5.63 (0.53) 
HR  CG  66.0 (6.5)  66.0 (6.5)  108.8 (8.6)  <0.001
  AG  59.7 (6.4)  59.7 (6.4)  111.6 (8.4) 
MAP  CG  93.7 (5.1)  102.5 (3.6)  86.1 (4.1)  0.035
  AG  96.3 (5.0)  102.5 (3.8)  81.5 (4.3) 
RBF  CG  217.3 (14.8)  217.3 (14.8)  324.8 (19.7)  0.194
  AG  214.7 (19.9)  214.7 (19.9)  292.3 (27.4) 
UO  CG  31.1 (7.1)  84.1 (20.4)  22.1 (4.8)  0.097
  AG  34.8 (7.0)  52.3 (17.4)  16.8 (11.0) 
TPC  CG  38.2 (3.4)  38.9 (3.4)  63.9 (6.8)  0.084
  AG  34.3 (3.1)  37.3 (3.2)  51.4 (6.8)  <0.001
SV  CG  51.4 (3.7)  39.1 (3.6)  35.5 (8.2)  0.147
  AG  51.2 (4.6)  36.7 (3.5)  39.6 (3.6) 
RVC  CG  2.39 (0.18)  3.26 (0.26)  3.74 (0.41)  0.55
  AG  2.23 (0.16)  2.88 (0.26)  3.53 (0.44) 
Values are the mean (± standard error). P value: two-way repeated-measures 
ANOVA interaction between treatment group and time (see text for defi  nitions).
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activity assay (EAA), cytokines, D-dimer, copeptin, and procalcitonin, in 
an adult population with sepsis.
Methods  Three North American study sites enrolled  adult patients 
within 24 hours of meeting at least two SIRS criteria with clinical 
evidence of infection. Biomarker sampling occurred daily on days 1 to 
7 and on days 14, 21, and 28. Clinical data from the 24 hours preceding 
the fi  rst sampling point as well as the baseline biomarker values were 
used as model inputs. Model outputs were serum creatinine (Scr) 
and organ metric (OM) over the study duration. OM is a composite 
parameter similar to the SOFA score with the CNS category removed 
and a continuous rather than categorical value. A neural net was used 
to perform a multiple parameter logistic regression while allowing for 
non-linear (usually sigmoidal) dependence on input parameters. Input 
parameters are fi  rst used individually to model the output and are then 
ranked based on the minimum mean squared error (MMSE) in these 
single-parameter models. The two parameters with the lowest MMSE 
are used to create the fi  nal multi-parametric model, which yields a 
lower modeling error than the original single-parameter models.
Results  Thirty patients were enrolled with the two most common 
infection types being pneumonia and bloodstream. Seventy per cent 
of patients had at least one organ failure at enrollment. Diastolic blood 
pressure (DBP), red blood cell count (RBC), and copeptin had the smallest 
MMSE when individually predicting OM. Combining DBP and RBC yielded 
good agreement between the modeled and actual OM value (r2 = 0.60). 
Individually, the prothrombin time (PT), copeptin, and phosphorus had 
the smallest MMSE when modeling Scr. The r2 value between the model 
and actual Scr was 0.64 when combining PT and copeptin.
Conclusion When analyzed using a neural net model, changes in overall 
organ dysfunction and serum creatinine were predicted from early 
clinical data in a population of adult patients with sepsis. Identifying 
predictive biomarker patterns and coupling this information with 
known drug/intervention response could aid in optimizing treatment 
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Introduction We have reported that nitric oxide (NO) production and 
microvascular hyperpermeability were signifi  cantly higher in septic 
sheep with methicillin-resistant Staphylococcus aureus (MRSA) than 
with  Pseudomonas aeruginosa. We hypothesize that peroxynitrite, 
a byproduct of NO, causes vascular hyperpermeability in MRSA 
sepsis via promoting vascular endothelial growth factor (VEGF) and 
Figure 1 (abstract P36). Hemodynamic variables during baseline and sepsis in the atenolol (AG, white circles, dotted line) and control (CG, black triangles, 
continuous line) groups.
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well-established ovine sepsis model and cultured human umbilical 
endothelial cells (HUVECs).
Methods Female ewes were chronically instrumented with multiple 
catheters and live MRSA (USA300, 1011 CFU) was instilled into the both 
lungs by bronchoscope under deep isofl  urane anesthesia. The sheep 
were then randomly allocated to control and treated (nonspecifi  c NOS 
inhibitor L-NAME, 25 mg/kg, i.v., every 12 hours) groups and monitored 
for 24 hours for cardiopulmonary hemodynamics. The cells were 
challenged with 105 CFU of live MRSA or 50 μM peroxynitrite and co-
incubated with or without L-NAME, peroxynitrite scavenger FeTMPyP, 
Tie-2 and Ang-2 antibody, and VEGF and its antibody. At diff  erent times 
after the treatment, the permeability was measured by quantifying 
the amount of FITC-Dextran that passed through the confl  uent HUVEC 
monolayer (n = 4). Ang-2 mRNA was determined by RT-PCR in those 
cells with or without treatment as well (n = 4). Statistical analysis: one-
way ANOVA (Bonferroni).
Results  In vivo, L-NAME signifi   cantly reduced MRSA-induced fl  uid 
accumulation and requirement, as well as expression of VEGF. HUVEC 
permeability was time-dependently increased following MRSA co-
incubation, reaching a plateau at 2 and 4 hours. These permeability 
changes (73 ± 4 RFUs) were signifi  cantly (P <0.001) inhibited by 1 mM 
L-NAME (28 ± 1), 5 μM FeTMPy (34 ± 2), 5 μg/ml Tie-2 antibody (32 ± 2), 
and 5 μg/ml Ang-2 antibody (30 ± 1). In HUVECs, the Ang-2 mRNA 
was time-dependently (picks at 30 minutes) and dose-dependently 
increased by peroxynitrite (highest at 50 μM). Treatment of HUVECs 
with 5 μM VEGF augmented the MRSA-induced Ang-2 mRNA increases. 
The latter was reversed with FeTMPyP and 5 μM VEGF antibody.
Conclusion  Ang-2 and VEGF, Tie-2 receptor, NO and its byproduct 
peroxynitrite play an important role in MRSA-induced vascular hyper-
permeability. The results strongly suggest that peroxynitrite increases 
vascular hyper-permeability by promoting Ang-2 release through 
stimulating the VEGF expression during MRSA-induced Gram-positive 
sepsis.
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Introduction  Although infectious diseases are the leading causes 
of death in sub-Saharan Africa, there are few studies describing 
sepsis in the region. Available data suggest that HIV prevalence is 
disproportionately high among septic patients and that treatment, 
particularly fl  uid administration, may be suboptimal [1]. Our study 
evaluated the clinical characteristics, management, and hospital 
outcomes of patients admitted with sepsis in Zambia. We hypothesized 
that patients with bacteremia have higher in-hospital mortality than 
those without.
Methods We conducted a prospective observational study of patients 
admitted with sepsis to the Adult Filter Clinic (medical ER) of the 
University Teaching Hospital (UTH) in Lusaka Zambia. Sepsis was 
defi  ned as two or more SIRS criteria and clinically suspected infection. 
Baseline characteristics and laboratory results were recorded, as 
was the timing of antibiotics and fl  uid administration. Patients were 
followed until discharge or death.
Results In 3 months, 161 septic patients were enrolled. One hundred 
and ten (68%) patients were HIV positive; 23 (14%) had unknown HIV 
status. Ninety-one (57%) had severe sepsis. Organ dysfunction included 
altered mentation (31%), renal dysfunction (16%), severe respiratory 
distress (respiratory rate ≥40) (11%), thrombocytopenia (11%), and 
hepatic dysfunction (7%). Multiple organ dysfunction occurred in 26%. 
After excluding contaminants, blood cultures were positive in 29 (18%) 
patients.  Staphyloccoccus aureus, salmonella species, Streptococcus 
pneumoniae, and Klebsiella pneumoniae were the most common 
pathogens. Only 29% of patients received intravenous fl  uids within 
1 hour of presentation. Eighty-four percent of patients received ≤1 l 
within the fi  rst 6 hours of presentation, and 55% received ≤1 l in the fi  rst 
24 hours. Overall in-hospital mortality was 40.4% (65/161). In-hospital 
mortality for severe sepsis was 54.9% (50/91). Important predictors 
for in-patient mortality (Table 1) were low Glasgow Coma Scale on 
admission (adjusted odds ratio (AOR) 16.0 (2.9 to 87.1)), positive blood 
culture (AOR 4.8 (1.5 to 15.0)), and positive and unknown HIV status 
(AOR 4.20 (1.0 to 17.0) and AOR 7.7 (1.2 to 47.7), respectively).
Conclusion In-hospital mortality due to sepsis is higher in Zambia than 
in most studies from the developed world. Low Glasgow Coma Scale 
and positive blood cultures are associated with increased in-hospital 
mortality. Insuffi   cient i.v. fl  uid administration probably contributes to 
the high overall mortality. Standardized management including early 
fl  uids and antibiotics might improve outcomes of sepsis and severe 
sepsis in sub-Saharan Africa.
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Introduction TNFα is thought to play a central role in the pathogenesis 
of sepsis and septic shock. AZD9773 is an ovine polyclonal anti-human 
TNFα immune Fab comprising TNFα-directed and nonspecifi  c  Fab 
populations. AZD9773 potency and pharmacokinetic attributes such as 
a shorter half-life distinguish it from anti-TNF monoclonal antibodies, 
which have been assessed previously in clinical sepsis models. Here 
we explore the preclinical safety/effi     cacy of AZD9773 in a mouse 
cecal ligation puncture (CLP) model. There are currently no reports 
of anti-TNF agent effi   cacy in mouse CLP; rather, TNFα neutralization 
Table 1 (abstract P40). Risk factors for in-hospital death
Variable  Adjusted OR  Crude OR
Anemia, Hb <9 g/dl  0.91 (0.74 to 4.93)  1.05 (0.56 to 1.80)
Blood culture positive  4.8 (1.50 to 15.0)  2.38 (1.14 to 4.95)
GCS  
 ≥13  1  1
  9 to 12  5.50 (1.90 to 16.20)  3.60 (1.60 to 8.11)
 <9  16.00 (2.90 to 87.10)  11.2 (3.50 to 36.4)
HIV  
 Negative  1  1
 Positive  4.20 (1.00 to 17.00)  2.35 (0.88 to 6.28)
 Unknown  7.70 (1.20 to 47.70)  8.38 (2.36 to 29.7)
<1 hour to IVF  0.40 (0.10 to 1.10)  0.86 (0.43 to 1.72)
MAP <65  2.10 (0.70 to 6.80)  1.25 (0.56 to 2.81)
IVF in fi  rst 6 hours   
 0  1  1
  1  0.80 (0.30 to 2.00)  0.81 (0.41 to 1.61)
  2 or more   0.30 (0.10 to 1.10)  0.60 (0.23 to 1.58)
Statistically signifi  cant ORs in bold.
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As AZD9773 is diff  erentiated from other anti-TNFα agents based on 
neutralizing potency and pharmacokinetic attributes, we studied both 
the safety and effi   cacy of this product in mouse CLP models.
Methods We studied AZD9773 (plus imipenem) eff  ects in two mouse 
CLP models: a mild-grade model to explore the potential for AZD9773 
to compromise mouse survival, and a severe-grade model to test 
AZD9773 effi     cacy. CLP (mild-grade sepsis) comprised 100% cecal 
ligation and single 20-gauge needle puncture, while CLP (severe-grade 
sepsis) comprised 100% cecal ligation and single 18-gauge needle 
puncture. Saline resuscitation and imipenem administration were 
included in both models. Since AZD9773 does not bind or neutralize 
murine TNFα, the CLP models were established in Tg1278/–/– (human 
TNFα transgene/mouse TNFα null) mice. An equivalent protein dose of 
DigiFab (plus imipenem) served as an irrelevant Fab control. Survival 
was monitored for 5 days.
Results  The control severe-grade model resulted in approximately 
20% survival at 5 days. Therapeutic i.p. dosing of AZD9773 bid from 
24 to 60 hours (fi  rst dose 4,000 units/kg, second to fourth doses 2,000 
units/kg) resulted in statistically signifi  cant increases in survival (>70%) 
compared with i.p. DigiFab control (n = 15 per group). The mild-grade 
model resulted in 63% survival with imipenem alone, 65% survival with 
AZD9773 and 69% survival with DigiFab at 5 days. Thus, therapeutic 
dosing of AZD9773 bid from 24 to 60 hours (schedule/dose/route as 
previously) did not result in signifi  cantly diff  erent survival outcomes 
versus either DigiFab or imipenem alone (n = 60 per group).
Conclusion  These data demonstrate for the fi   rst time that TNFα 
neutralization in a murine CLP model improves survival in a severe 
sepsis setting. Moreover, contrasting with previous reports, TNF 
suppression in mild-grade CLP models is not associated with increased 
mortality. These fi   ndings support the hypothesis that AZD9773 
has potential to be diff  erentiated from other anti-TNF agents as a 
therapeutic intervention in sepsis.
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Introduction Endotoxin plays a role in the development of Gram-
negative bacterial sepsis. In Japan, polymyxin B-attached fi  bers 
(PMX-B) are used clinically as an endotoxin absorption therapy to 
neutralize the biological activity of lipid A, the immunomodulatory 
center of lipopolysaccharide (LPS) endotoxin. Because hemodynamic 
improvement is not seen in all cases, it cannot be assumed that this 
therapy will be eff  ective against all cases of sepsis.
Hypothesis Endotoxin absorption therapy is eff  ective  against 
abdominal infection. Moreover, the mortality rate signifi  cantly 
improved in endotoxin-positive cases of abdominal infection.
Methods Between 1997 and April 2008, endotoxin absorption therapy 
was performed on 105 septic patients in the ICU of Hyogo College 
of Medicine and the Osaka City General Hospital. The 105 cases were 
divided into an abdominal infection group (n = 45) and a nonabdominal 
infection group (n = 60). Before and after therapy, the endotoxin level 
was measured in patients using the limulus amoebocyte lysate (LAL) and 
endotoxin activity assay (EAA) methods. Moreover, we measured blood 
pressure, cardiac index, and the administered dose of catecholamine. 
Using a retrospective analysis, we compared Sequential Organ Failure 
Assessment (SOFA) scores; the Risk, Injury, Failure, Loss, and End stage 
(RIFLE) criteria; and the 28-day survival rate between the two groups.
Results After the endotoxin absorption therapy, mean blood pressure 
increased signifi  cantly from 67.9 ± 11.4 to 86.4 ± 6.3 mmHg in the 
abdominal infection group, whereas there was no change in the 
nonabdominal infection group. After the therapy, the SOFA scores and 
RIFLE criteria improved in both groups, but they improved signifi  cantly 
in the abdominal infection group. Patients in the abdominal infection 
group, especially the endotoxin-positive cases, recovered earlier from 
shock and had a signifi  cantly higher rate of survival than the abdominal 
infection group.
Conclusion In endotoxin-positive patients with an abdominal infection, 
absorption therapy improved survival rate and cardiac and renal 
dysfunction due to sepsis or septic shock. However, further studies are 
required to verify the eff  ectiveness of endotoxin absorption therapy.
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Introduction  Severe sepsis is major health problem with a high 
mortality rate, and still its incidence continues to rise [1-5]. Lactate 
clearance, measurement of the lactate level at two consecutive times, 
is an inexpensive and simple clinical parameter that can be obtained 
by a minimally invasive means [6-8]. This parameter represents kinetic 
alteration of the anaerobic metabolism that makes it a potential 
parameter to evaluate disease severity and intervention adequacy. 
Lactate clearance early in the hospital course may indicate a resolution 
of global tissue hypoxia and is associated with improved outcome 
[7-9]. Nevertheless, the relationship between lactate clearance and 
short-term mortality in severe septic patients is still poorly understood. 
Understanding the presence of confounder factors is also important 
to strengthen the role of lactate clearance in the treatment of severe 
septic patients.
Objective To evaluate the clinical course between lactate clearance 
groups, and determine the role of confounder variables that infl  uence 
its relationship.
Methods This is a prospective cohort study conducted in Ciptomangun-
kusumo Hospital, from March to May 2011. Patients were categorized 
into the high lactate clearance group if there were diff  erences in 6-hour 
lactate levels ≥10%, and conversely were categorized into the low 
lactate clearance group [7,8]. Deaths were observed within the fi  rst 
10 days. After data collection, the statistical methods were analyzed 
using survival analysis. Analysis of confounder variables was performed 
by multivariate Cox regression test.
Results During the research period there were 60 patients recruited, 
consisting of 30 patients grouped into high lactate clearance and the 
remainder grouped into low lactate clearance. The survival rates in 
high and low lactate clearance groups were 60.0% versus 26.7% (see 
Figure 1). In the low lactate clearance group the median survival was 
3 days, while the mortality rate did not reach 50% in the high lactate 
clearance group. The fi  rst interquartile was 1 day and 4 days. The hazard 
ratio between groups was 2.87 (95% CI = 1.41 to 5.83). Steps taken to 
analyze the role of variables that potentially act as confounder factors 
Figure 1 (abstract P43). Kaplan–Meier curves between lactate clearance 
groups.
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occurrence of deaths (indicated by P <0.25) underwent multivariate 
analysis subsequently. On multivariate analysis the presence of septic 
shock, degree of organ dysfunction, vasoactive drug usage, blood 
transfusion, and fl   uid resuscitation change the hazard ratio by no 
more than 10% (Table 1). For that reason, these parameters were not 
considered as confounders.
Conclusion Severe septic patients with high lactate clearance have a 
better survival rate compared with the low lactate clearance group, 
and its relationship is not infl  uenced by the presence of confounder 
variables.
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Introduction  The use of low-dose corticosteroids in sepsis early 
stages is still debated. The association of LPS–LBP complexes to CD14 
receptors and will interact with TLR4 to induce NF-κB as a signal and 
transcription of proinfl  ammatory cytokines [1,2]. Excessive production 
of infl  ammatory cytokines will cause activation of SIRS, especially in 
gut-associated lymphoid tissues [3], which induces metabolic changes 
leading to apoptosis network, MOF, septic shock and death [3-5]. 
Changes in apoptosis are mediated by caspases, including caspase-3 
that acts as an eff  ector caspase [6,7]. Low-dose corticosteroids can 
inhibit the production of proinfl   ammatory cytokines, production 
of infl  ammatory mediators, and lower adhesion of leukocytes to the 
endothelium [8].
Objective The aim of this study was to analyse NF-κB and caspase-3 
intestinal expression, and also survival from use of low-dose steroid in 
the early stages of sepsis in the Balb/C mouse model of sepsis.
Methods Male Balb/C mice were inoculated with lipopolysaccharide 
for the sepsis mouse model. Sepsis mouse model grouping was to a 
sepsis group (Group I) and to sepsis with steroid (methylprednisolone 
1 to 1.5 mg/kg BW/day) (Group II). Detection of intestinal NF-κB and 
caspase-3 expression used the immunohistochemistry technique on 
days 1, 3, 5 and 7. Survival was seen until the 7th day. The two-tailed 
Fisher exact test for the analysis of mortality, independent-sample t test 
for intestinal NF-κB and caspase-3 expression, and P <0.05 were used to 
determine signifi  cant diff  erences.
Results  Acute infl  ammatory response occurs in the early stages of 
sepsis (the fi  rst 5 days of exposure) and the process of death occurs in 
advanced stages of sepsis (after the fi  rst 5 days of exposure) [9]. This 
study shows that the use of low-dose corticosteroids in sepsis early 
stages (fi  rst 5 days) signifi  cantly inhibited the expression of NF-κB (see 
Table 1), so cytokine production of proinfl  ammatory cytokines was not 
excessive. Reduced product proinfl  ammatory cytokines would reduce 
the expression of intestinal caspase-3 (see Table 2), which will reduce 
Table 1 (abstract P43). Variables that potentially act as confounder factors
Variable Nonsurvivors  Survivors  P value  Adjusted HR (95% CI)  HR change (%)
Septic shock within 6 hours         
  With septic shock  11  4  0.081  3.083 (1.505 to 6.317)  7.4
  Without septic shock  23  22     
Initial  SOFA  score      
  >9  11  3  0.038  2.919 (1.388 to 6.138)  1.7
 ≤9  19  21     
Vasoactive drugs within 6 hours         
  Without vasoactive drugs  22  23  0.013  2.988 (1.462 to 6.106)  4.1
  With vasoactive drugs  12  3     
Invasive ventilation within 6 hoursa      
  Without mechanical ventilation  31  23  0.777  –  –
  With mechanical ventilation  3  3     
PRC transfusion within 6 hours         
  Without transfusion  29  25  0.069  3.077 (1.493 to 6.340)  7.2
 With  transfusion  5  1     
Fluid resuscitation within 6 hours         
 <1,000  cm3  15  18  0.166  2.942 (1.444 to 5.994)  2.5
 ≥1,000  cm3   19  8     
HR, hazard ratio; SOFA, Sequential Organ Failure Assessment; PRC, packed red cells. aInvasive ventilation parameter not included in multivariate analysis, because 
P <0.25.
Critical Care 2011, Volume 15 Suppl 3 
http://ccforum.com/supplements/15/S3
S22the excessive apoptosis in the intestinal tract. Decreased expression of 
NF-κB and caspase-3 in the intestinal tract would further reduce the 
excessive mucosal cell death. This situation will block the destruction 
and disruption of mucosal defense function of the digestive tract, 
thereby increasing immune response. The end result will be seen that 
low-dose corticosteroids can reduce mortality. This study found dead 
animals for Group I were 70%, while Group II were 10% (P = 0.020).
Conclusion  Low-dose steroids can reduce NF-κB and caspase-3 
intestinal expression and also mortality in early sepsis.
Acknowledgements  The authors thank the Faculty of Medicine, 
University of Sebelas Maret for their fi  nancial support and assistance 
given in this study.
References
1.  Hongwei Q, Cynthia AW, Sun JL, Xueyan Z, Etty NB: LPS induces CD40 gene 
expression through the activation of NF-κB and STAT-1α in macrophages 
and microglia. Blood 2005, 106:3114-3122.
2.  Kristine MJ, Sarah BL, Anncatrine LP, Jesper EO, Thomas B: Common TNF-α, 
IL-1β, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with 
disease severity or outcome from gram negative sepsis. BMC Infect Dis 
2007, 7:108.
3.  Arul MC, Markus HL, Chandan KS, Terrence RB, Sunita SS, Vidya JS, Vaishalee 
AP, Peter AW: Molecular signatures of sepsis multiorgan gene expression 
profi  les of systemic infl  ammation. Am J Pathol 2001, 159:1199-1209.
4.  Elena GR, Alejo C, Gema R, Mario D: Cortistatin, a new antiinfl  ammatory 
peptide with therapeutic eff  ect on lethal endotoxemia. J Exp Med 2006, 
203:563-571.
5.  Javier C, José Y, David HE, Yolanda M, Ruben M, Isabel A, Antonia M, Pascual P, 
Vicente V: Role of lipopolysaccharide and cecal ligation and puncture on 
blood coagulation and infl  ammation in sensitive and resistant mice 
models. Am J Pathol 2005, 166:1089-1098.
6.  Chung CS, Chaudry IH, Ayala A: The apoptotic response of the lymphoid 
immune system to trauma, shock and sepsis. In Yearbook of Intensive Care 
and Emergency Medicine. Editted by Vincent JL. Berlin: Spinger-Verlag; 
2000:27-40.
7.  Chung CS, Song GY, Lomas J, Simms HH, Chaudry IH, Ayala A: Inhibition of 
Fas/Fas ligand signaling improves septic survival: diff  erential eff  ects on 
macrophage apoptotic and functional capacity. J Leukoc Biol 2003, 
74:344-351.
8.  Annane D, Caillon DM: Corticosteroid in sepsis: from bench to bedside. 
Shock 2003, 20:197-207.
9.  Xiao H, Siddiqui J, Remick DG: Mechanisms of mortality in early and late 
sepsis. Infection Immunity 2006, 74:5227-5235.
P45
Etiological agents of bacterial sepsis in a newly constructed medical 
center in Saint Petersburg, Russia
E Barantsevich, N Barantsevich, N Rybkova, I Churkina, N Pestova, 
M Karpenko
Almazov Federal Center of Heart, Blood and Endocrinology, Saint Petersburg, 
Russia
Critical Care 2011, 15(Suppl 3):P45 (doi: 10.1186/cc10414)
Introduction Sepsis is one of the factors of high mortality in ICUs in 
critically ill patients. Annual mortality from this condition is estimated 
at 30 to 50 deaths per 100,000 population [1,2,4,5]. The aim of the 
present study was to reveal the spectrum and resistance to antibiotics 
of microorganisms, causing sepsis in hospitalized patients of the 
multidisciplinary medical center, that accumulates patients from all 
regions of Russia, during the fi  rst year from its foundation, with low 
possibility of local nosocomial strains formation.
Methods The diagnosis of sepsis was verifi  ed by isolation of bacteria 
from blood (only two or more positive results were considered) and the 
presence of two or more criteria of systemic infl  ammatory response 
syndrome [3]. The cultures were isolated from blood with BactAlert 
(BioMerieux, France). The identifi   cation was performed by routine 
phenotypic methods and sequencing of the 16sRNA gene (ABI Prism 
3130, MicroSeq ID v2.0 Software, MicroSeq ID 16s rDNA500 Library 
v2.0). Resistance to routinely used antibiotics was investigated with the 
disc diff  usion method and by dilution techniques for MIC determination 
on Muller–Hinton agar (Oxoid, UK).
Results Sepsis, associated with bloodstream infections, was revealed 
in 89 cases – Gram-positive cocci predominated. Staphylococcus spp. 
were responsible for 35 (39.3%) cases: Staphylococcus aureus was the 
causative agent in eight (8.9%), coagulase-negative staphylococci 
(Staphylococcus  epidermidis, Staphylococcus haemolyticus, Staphylo-
coccus hominis novobiosepticus) in 27 (30.3%) infections. Other Gram-
positive cocci were Enterococcus faecalis in eight (8.9%), Enterococcus 
faecium in six (6.7%). Gram-negative microorganisms included Acineto-
bacter baumannii that was found in 11 (12.4%), Klebsiella spp. (Klebsiella 
pneumonia, Klebsiella rhinoscleromatis, Klebsiella oxytoca) in fi  ve 
(5.6%), Escherichia coli in eight (8.9%), Enterobacter spp. (Enterobacter 
cloaceae, Enterobacter aerogenes, Enterobacter hormaechea)  in three 
(3.4%),  Pseudomonas aeruginosa in two (2.2%) patients with sepsis. 
Rarely isolated bacteria were Bacillus thuringiensis in one (1.1%), 
Stenotrophomonas maltophylia in one (1.1%), Pantoeae agglomerans in 
one (1.1%), Corynebacterium mucifaciensis in one (1.1%) case. Two and 
more species were isolated from blood in seven (7.9%) patients. In total, 
105 strains were isolated in sepsis cases. Resistance to antibiotics was 
observed in 96 (91.4%) bacterial isolates; 56 (53.3%) were multidrug-
resistant strains. All E. faecium, and nine (81.8%) strains of A. baumannii 
were resistant to seven or more antibiotics. All E. faecium strains were 
susceptible to linezolide, A. baumannii to tigecycline. Methicillin 
resistance was detected in two (15.4%) strains of S. aureus and 18 
(60.0%) strains of coagulase-negative staphylococci; four (66.7%) 
strains of E. faecium were vancomycin resistant.
Conclusion Gram-positive bacteria were the leading causative agents 
of sepsis, associated with bloodstream infections in the newly-
constructed hospital in Saint Petersburg. The majority of strains (91.4%) 
were resistant to antibiotics, and more than half of the isolates were 
multidrug resistant. Methicillin resistance was observed predominantly 
in coagulase-negative staphylococci, vancomycin resistance in 
E.  faecium. All polyresistant E. faecium strains were susceptible to 
linezolide, A. baumannii to tigecycline.
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Table 1 (abstract P44). NF-κB intestinal expression
  Amount of cell expression
Day  Group I  Group II  P value
1  17.5 ± 4.7  10.8 ± 3.6  0.019
3  26.5 ± 4.4  15.8 ± 3.6  0.001
5  39.3 ± 4.1  31.2 ± 7.0  0.033
7  54.8 ± 9.6  50.5 ± 10.7  0.476
Data presented as mean ± standard deviation.
Table 2 (abstract P44). Caspase-3 intestinal expression
  Amount of cell expression
Day Group  I  Group II  P value
1  8.5 ± 2.9  4.3 ± 1.9  0.014
3  14.7 ± 3.1  9.8 ± 2.2  0.012
5  33.2 ± 8.3  12.8 ± 4.5  0.000
7  42.3 ± 3.2  37.7 ± 8.2  0.336
Data presented as mean ± standard deviation.
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Introduction Gelatin is frequently used as volume expander. There are 
growing concerns about safety.
Objective  To systematically assess clinical evidence concerning 
mortality, coagulation and renal function.
Methods  Systematic review of randomised controlled trials (RCT) 
on gelatin in hypovolemia in comparison to any other fl  uid  with 
a comprehensive search strategy (Ovid Medline (1948 to May 
2011), EMBASE (1947 to May 2011), Cochrane Library). Data were 
independently extracted and risk of bias assessed using the 2010 
Cochrane tool. Primary outcome was overall mortality. Secondary 
outcomes were the number of patients exposed to allogeneic 
transfusion, frequency of renal replacement therapy (RRT) or acute 
renal failure (ARF). Albumin and crystalloid solutions were defi  ned as 
suitable, and other synthetic colloids as unsuitable control fl  uids since 
they carry similar risk of side eff  ects. Relative risks (RR) and weighted 
mean diff  erences with 95% CIs were calculated. Data were pooled 
using a random-eff  ects model (RevMan 5.1, Cochrane Collaboration).
Results The search yielded 1,288 citations, 210 reports were read in 
full. The fi  nal sample contained 72 RCT in English, German, French and 
Italian, published between 1975 and 2010, with 5,915 patients overall, 
2,523 of which received gelatin. The median sample size in the gelatin 
groups was 20 patients (range 10 to 249). In 53 RCT (74%), the study 
period was ≤24.0 hours. Total gelatin dose was 20 ml/kg (median, 
range 6 to 62). Only 38 RCT (53%) used suitable control fl  uids. Forty-
nine RCT (68%) investigated elective surgical patients, mostly from 
cardiac surgery (32 RCT, 44%). Nine RCT (13%) investigated critically ill 
patients, six RCT (8%) were in emergency patients and seven RCT (10%) 
were in children. The RR for mortality was 1.02 (CI 0.87 to 1.19, data 
from 23 RCT with 2,694 patients which reported mortality). Numbers of 
patients exposed to allogeneic transfusions were provided in 11 RCT, 
n = 1,148 patients and the RR was 1.16 (0.94 to 1.44). When only studies 
with suitable control fl  uids were included, the RR for mortality was 1.13 
(0.88 to 1.46, 10 RCT, 1,392 patients) and risk for transfusion exposure 
was 1.35 (0.88 to 2.08, seven RCT, n = 672), tending towards control. 
Only six RCT (n = 662 patients) reported the occurrence of RRT or ARF, 
fi  ve of them in comparison with HES solutions. Three RCT reported 
anaphylactoid events.
Conclusion Most published studies on gelatin are small and short-
time, use unsuitable control fl  uids and report too few events to reliably 
assess the safety of gelatin.
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